Novel Hypotheses from TRPM3 Ion Channel Research

TRPM3 (Transient Receptor Potential Melastatin 3) ion channel dysfunction is one of the most consistently replicated findings in ME/CFS research, with evidence accumulating across multiple independent studies and research groups. Nguyen et al. (2017) first identified reduced TRPM3 surface expression and impaired Ca²⁺ mobilization in CD56bright NK cells from ME/CFS patients (Nguyen et al. 2017). Cabanas et al. (2019) confirmed this with whole-cell patch-clamp electrophysiology, demonstrating significantly reduced TRPM3 current amplitude using multiple pharmacological probes (pregnenolone sulfate, nifedipine, ononetin) (H. Cabanas et al. 2019). Eaton-Fitch et al. (2021) showed reduced TRPM3/PIP₂ co-localization, linking channel dysfunction directly to impaired NK cell degranulation and failed perforin/granzyme release (Eaton-Fitch et al. 2021). A subsequent study confirmed that Ca²⁺ influx amplitude is significantly reduced at baseline (p < 0.0001) and that overnight naltrexone fully restores TRPM3-dependent Ca²⁺ influx (Eaton-Fitch et al. 2022). The 2026 multi-site validation by Sasso et al. (n=78) (Sasso et al. 2026) confirms the finding as robust. TRPM3 is not merely an immune cell ion channel—it is expressed across multiple tissue types and participates in diverse physiological processes. This reproducible finding suggests several novel hypotheses.

1 The Paradoxical Immune State Hypothesis

Open Question: Stuck Doors Explain Simultaneous Over- and Under-Activity

ME/CFS presents a puzzling immunological paradox: the immune system appears simultaneously overactive (chronic inflammation, elevated cytokines, persistent immune activation markers) and underactive (impaired NK cell cytotoxicity, poor pathogen clearance, T cell exhaustion). How can both be true?

TRPM3 dysfunction provides an elegant resolution. Consider immune cells as soldiers who can see the enemy but whose weapons won’t fire:

Proposed mechanism:

Immune cells (NK cells, T cells) recognize pathogens or infected cells normally
Upon recognition, they attempt to degranulate and release cytotoxic mediators
Degranulation requires calcium influx through channels including TRPM3
With TRPM3 dysfunction (“stuck doors”), calcium influx is impaired
The cell cannot complete the kill—degranulation fails or is incomplete
The target survives; the immune cell signals for reinforcements
More immune cells are recruited, more activation signals are released
Chronic inflammation results from persistent, frustrated immune responses
Meanwhile, actual pathogen clearance fails, permitting viral persistence

This creates a vicious cycle: inflammation without resolution. The immune system keeps trying but never succeeds. Cytokine alarms stay elevated because the underlying threat is never neutralized. Energy is consumed in futile immune activation.

Predictions.

NK cells from ME/CFS patients should show normal target recognition but impaired degranulation
Calcium flux measurements during degranulation attempts should show reduced amplitude or kinetics
Inflammatory markers should correlate with degree of TRPM3 dysfunction
Patients with more severe TRPM3 impairment should show poorer pathogen control

2 The TRPM3-GPCR Signaling Convergence Hypothesis

Open Question: Autoantibodies and Ion Channels: Connected Dysfunction

GPCR autoantibodies (anti-\(\beta_2\)-adrenergic, anti-muscarinic) are documented in ME/CFS. TRPM3 dysfunction is now also documented. Are these independent abnormalities, or connected?

TRPM3 gating is modulated by G-protein signaling pathways. Muscarinic receptor activation, for example, can influence TRP channel function through phospholipase C and intracellular calcium stores. If autoantibodies are chronically dysregulating GPCR signaling, they might indirectly cause or exacerbate TRPM3 dysfunction.

Possible connections:

GPCR autoantibodies → aberrant second messenger signaling → altered TRPM3 phosphorylation → channel dysfunction
Chronic receptor stimulation → depletion of PIP₂ (required for TRP channel function) → reduced TRPM3 activity
Autoantibody-induced receptor internalization → loss of TRPM3-regulating GPCR pathways → unregulated channel states
Alternatively: shared autoimmune targeting of GPCRs and ion channels

If GPCR dysfunction and TRPM3 dysfunction are linked, therapies targeting autoantibodies (immunoadsorption, BC007, daratumumab) might restore both GPCR signaling and TRPM3 function.

Testable predictions.

GPCR autoantibody titers should correlate with severity of TRPM3 dysfunction
Removal of autoantibodies should improve TRPM3 function measurements
In vitro, adding ME/CFS patient IgG to healthy cells should impair TRPM3 responses
TRPM3 agonists might partially rescue function even in presence of autoantibodies

3 The Systemic Channelopathy Hypothesis

Open Question: TRPM3 Dysfunction Beyond Immune Cells

The Sasso et al. study demonstrated TRPM3 dysfunction specifically in immune cells. However, TRPM3 is not limited to immune cells—it is expressed in:

Sensory neurons (particularly nociceptors)
Pancreatic \(\beta\)-cells (insulin secretion)
Vascular smooth muscle
Kidney epithelium
Brain (various regions)
Retinal ganglion cells

What if TRPM3 dysfunction in ME/CFS is systemic—affecting all tissues where the channel is expressed?

Predicted consequences by tissue:

Sensory neurons:

TRPM3 is a heat and pain sensor
Dysfunction could cause: altered temperature perception, cold intolerance, heat intolerance, hyperalgesia, allodynia. ET-1-mediated tonic vasoconstriction (ch10:Tonic Cutaneous Vasoconstriction Bias Explains Dual Heat+Cold Intolerance) and impaired mitochondrial reserve for thermoregulatory work (ch06:Spare Respiratory Capacity as Thermoregulatory Capacity Proxy in ME/CFS) may amplify these symptoms downstream of TRPM3 dysfunction.
The characteristic sensory hypersensitivities of ME/CFS might be direct TRPM3 effects

Pancreatic \(\beta\)-cells:

TRPM3 modulates insulin secretion
Dysfunction could cause: reactive hypoglycemia, postprandial symptoms, glucose intolerance
Many ME/CFS patients report blood sugar instability

Vascular smooth muscle:

TRPM3 affects vascular tone
Dysfunction could cause: abnormal blood pressure regulation, orthostatic intolerance
Connects to POTS and orthostatic symptoms

Brain:

TRPM3 in neurons affects excitability
Dysfunction could cause: cognitive impairment, altered neurotransmission
May contribute to “brain fog” directly, not just via inflammation

If TRPM3 dysfunction is systemic, ME/CFS is fundamentally a channelopathy—a disease of ion channel function affecting multiple organ systems simultaneously.

Research implications.

TRPM3 function should be tested in multiple cell types from ME/CFS patients
Symptoms should cluster by TRPM3-expressing tissues
Treatments restoring TRPM3 function might address multiple symptom domains simultaneously

4 The “Wired but Tired” Ion Channel Explanation

Hypothesis: Bidirectional Channel Dysfunction Creates Paradoxical State

Certainty: 0.40. The “wired but tired” phenomenon—feeling simultaneously exhausted and unable to relax—is a hallmark of ME/CFS. Ion channel dysfunction offers a mechanistic explanation:

Proposed mechanism:

The Sasso et al. study found TRPM3 dysfunction characterized as channels that fail to allow adequate calcium entry (“stuck doors”). However, ion channel dysfunction can theoretically manifest in multiple ways:
- Stuck closed → inability to respond to physiological stimuli (consistent with the study findings)
- Stuck partially open → chronic low-level calcium leak (speculative alternative)
- Altered gating kinetics → inappropriate timing of responses
In sensory neurons, a partially open channel would cause:
- Baseline hyperexcitability
- Lowered activation thresholds
- Spontaneous firing → restlessness, hypersensitivity
In immune and muscle cells, impaired channel response would cause:
- Failed energy-requiring processes
- Calcium-dependent enzyme dysfunction
- Fatigue and weakness
The same patient has hyperactive sensory processing (“wired”) AND dysfunctional effector mechanisms (“tired”)

This is not contradictory—it is the expected result of ion channel dysfunction affecting excitable and effector cells differently. The nervous system is overexcitable while the muscular and immune systems are underpowered.

5 The Calcium-Mitochondria Cascade Hypothesis

Limitation: Working Model: Evidence from Separate Studies, Not an Integrated Pathway

The hypotheses in the following sections (calcium-mitochondria cascade, post-infectious acquisition, temperature dysregulation, TRP channel sensitization, Piezo channels) assemble evidence from studies in different cell types, species, and research groups. No study has demonstrated this cascade end-to-end in a single ME/CFS patient cohort. The integration is a working model intended to generate testable predictions, not a description of established pathophysiology.

Open Question: TRPM3 Dysfunction Upstream of Mitochondrial Failure

Mitochondrial dysfunction is well-documented in ME/CFS: impaired oxidative phosphorylation, reduced ATP production, abnormal metabolomics. But is mitochondrial dysfunction primary or secondary?

Calcium and mitochondria are intimately linked:

Mitochondria buffer cytosolic calcium
Mitochondrial calcium uptake regulates the TCA cycle and oxidative phosphorylation
Calcium signals promote ATP synthesis by activating matrix dehydrogenases
Both calcium overload and calcium depletion impair mitochondrial function

What if TRPM3 dysfunction causes mitochondrial dysfunction?

Proposed mechanism:

TRPM3 dysfunction alters cellular calcium handling
Scenario A (stuck closed): Cells cannot achieve adequate calcium transients
- Insufficient calcium signaling to mitochondria
- Reduced activation of calcium-dependent metabolic enzymes
- Impaired ATP production under demand
Scenario B (stuck partially open): Chronic calcium leak
- Mitochondria continuously buffer excess calcium
- Mitochondrial calcium overload → oxidative stress
- Gradual mitochondrial damage
Either scenario results in energy deficit
The observed mitochondrial dysfunction is downstream of ion channel dysfunction

If true, treating the mitochondria (CoQ10, ribose, carnitine) addresses symptoms but not cause. Restoring TRPM3 function would restore mitochondrial function automatically.

Predictions.

TRPM3 dysfunction severity should correlate with mitochondrial dysfunction severity
Restoring TRPM3 function should improve mitochondrial parameters
Mitochondrial therapies without TRPM3 restoration should show limited, temporary benefit
Calcium imaging during cellular stress should show abnormal patterns in ME/CFS

6 The Post-Infectious TRPM3 Acquisition Hypothesis

Open Question: How Does Infection Lead to Channel Dysfunction?

If TRPM3 dysfunction is acquired after infection (as suggested by post-infectious onset of ME/CFS), what mechanism causes it?

Possible mechanisms:

Viral interference with ion channels. Some viruses directly modulate host ion channels during infection—this aids viral replication or immune evasion. If the modulation leaves persistent modifications (oxidative damage, altered phosphorylation, protein misfolding), the channel might remain dysfunctional after the virus is cleared.

Autoimmune targeting. Molecular mimicry between viral proteins and TRPM3 epitopes could generate cross-reactive antibodies or T cells. The immune response intended for the virus attacks the patient’s ion channels. This would be analogous to Guillain-Barré syndrome (anti-ganglioside antibodies after Campylobacter) but targeting TRPM3.

Epigenetic modification. Severe infection causes oxidative and metabolic stress. This can create epigenetic marks (DNA methylation, histone modifications) affecting gene expression. TRPM3 expression or its regulatory proteins might be persistently downregulated.

Membrane composition changes. Ion channel function depends on the surrounding lipid environment. Infection-induced changes in membrane lipid composition (documented in ME/CFS) might alter TRPM3 gating properties even without changes to the protein itself.

Cofactor depletion. TRPM3 function may require specific cofactors or post-translational modifications. If infection depletes these (e.g., zinc, selenium, PIP₂), and they are not fully restored during recovery, channel function remains impaired.

Research directions.

Screen ME/CFS patients for anti-TRPM3 autoantibodies
Examine TRPM3 gene methylation patterns
Test whether ME/CFS serum alters TRPM3 function in healthy cells
Compare TRPM3 function immediately post-infection vs. established ME/CFS

7 The Temperature Dysregulation Connection

Hypothesis: TRPM3 as the Missing Link in Thermoregulation

Certainty: 0.35. ME/CFS patients commonly report:

Feeling cold when ambient temperature is normal
Inability to regulate body temperature
Symptom flares with temperature changes
Intolerance to both heat and cold
Subjective fever without measurable temperature elevation

TRPM3 is a thermosensor—it responds to temperature changes, particularly in the warm/noxious heat range. In sensory neurons, TRPM3 contributes to heat detection and thermal pain.

Proposed mechanism:

Dysfunctional TRPM3 in sensory neurons provides incorrect temperature information
The brain receives aberrant thermosensory input
Thermoregulatory centers cannot properly assess or maintain body temperature
The patient feels cold (despite normal core temperature) or hot (without fever)
Thermoregulatory behaviors (seeking warmth, sweating) become maladaptive
Temperature instability is not an epiphenomenon but a direct consequence of TRPM3 dysfunction

This reframes temperature symptoms from “vague subjective complaints” to objective consequences of ion channel pathology.

Limitation: TRPM3 Hypotheses: Single Research Group, In Vitro Scope

The TRPM3 dysfunction finding has been reported across multiple sites (Sasso et al. 2026), but all studies to date originate from the same research network (Cabanas/Marshall-Gradisnik, Griffith University/NCNED). Multi-site is not the same as independent validation when the sites are within the same network. The following boundaries constrain the hypotheses built on this evidence:

TRPM3 dysfunction has been demonstrated only in immune cells (NK cells, T cells); the “systemic channelopathy” hypothesis—that TRPM3 is dysfunctional in sensory neurons, pancreatic \(\beta\)-cells, vascular smooth muscle, and brain—is extrapolation, not measurement.
Three distinct causal hypotheses for TRPM3’s role must be distinguished, as they have opposite therapeutic implications:
- Causal hypothesis: TRPM3 dysfunction is a primary pathogenic mechanism; correcting TRPM3 should improve symptoms. This underpins all TRPM3-targeted therapeutic speculation in this chapter.
- Consequential hypothesis: TRPM3 dysfunction is a downstream consequence of chronic immune activation, redox stress, or altered membrane lipid composition caused by the disease—all of which modulate TRP channel gating independently of primary TRPM3 pathology. Correcting TRPM3 would not address the upstream cause.
- Biomarker hypothesis: TRPM3 dysfunction is a reliable marker of NK cell state in ME/CFS with no direct causal role; useful diagnostically but not therapeutically. Available cross-sectional data cannot distinguish between these three; prospective intervention studies are required.
The proposed TRPM3-GPCR signaling convergence and calcium-mitochondria cascade are mechanistically plausible models, but the causal links (autoantibodies \(\to\) TRPM3 dysfunction \(\to\) mitochondrial failure) have not been demonstrated in any experimental system.
Therapeutic speculation regarding TRPM3 agonists/antagonists is premature: TRPM3 pharmacology in humans is poorly characterized, and no TRPM3-modulating compound has been tested in ME/CFS patients.

8 TRPM3-Targeted Therapeutic Speculation

If TRPM3 dysfunction is central to ME/CFS pathophysiology, targeting TRPM3 pharmacologically becomes attractive:

If channels are “stuck closed” (hypofunction):

TRPM3 agonists might restore function
Pregnenolone sulfate (endogenous neurosteroid) activates TRPM3
CIM0216 is a potent synthetic TRPM3 agonist (research tool, not approved drug)
Nifedipine paradoxically activates TRPM3 at certain concentrations
Speculation: If TRPM3 hypofunction underlies symptoms, pregnenolone sulfate supplementation might theoretically help—but this has not been tested

If channels are “stuck open” (leak/hyperfunction):

TRPM3 antagonists might restore proper gating
Primidone (anti-epileptic) blocks TRPM3
Certain flavonoids (naringenin, isosakuranetin) inhibit TRPM3
Caution: Blocking an already dysfunctional channel might worsen symptoms

Restoring channel environment:

Membrane lipid composition affects TRP channel function
Omega-3 fatty acids might normalize membrane environment
PIP₂ repletion strategies (inositol supplementation?)
Reducing oxidative damage to channel proteins (antioxidants)

Addressing upstream causes:

If autoantibodies cause TRPM3 dysfunction: immunoadsorption, rituximab, daratumumab
If viral proteins interfere: antivirals
If epigenetic: theoretically, epigenetic modifiers (speculative, no specific candidates)

Warning: Highly Speculative Therapeutics

These therapeutic ideas are entirely speculative. TRPM3 pharmacology in humans is poorly characterized. No clinical trials have tested TRPM3 modulators in ME/CFS. Self-experimentation with TRPM3-active compounds is not recommended. These ideas are presented to stimulate research, not to guide treatment.

9 Two Calcium Subtypes: A Unifying Framework

Speculation: Subtype A vs Subtype B: Two Distinct Calcium Mechanisms in ME/CFS

The calcium mechanisms documented across ME/CFS research do not represent a single unified pathway. They fall into two mechanistically distinct subtypes with opposite causal logic and potentially different therapeutic implications.

Subtype A — Energy Failure Leading to Secondary Calcium Dysregulation

Calcium overload is downstream of metabolic and vascular crisis. The proposed cascade (Section WASF3–DRP1 Convergence: Two Routes to the Same Mitochondrial Failure): capillary hypoperfusion → anaerobic metabolism → proton accumulation → NHE1 sodium influx → Na⁺/K⁺-ATPase saturation → NCX1 reversal → intracellular Ca²⁺ overload. This is a well-characterized pathophysiology that predicts muscle necrosis during PEM (Wirth and Scheibenbogen 2024) and is supported by sodium MRI evidence (Wirth and Scheibenbogen 2022). The calcium dysregulation is real and damaging, but it is secondary to the upstream energy/vascular failure. Correcting the upstream hypoperfusion or restoring Na⁺/K⁺-ATPase function (e.g., MDC002/Mitodicure) should prevent the calcium cascade from reaching the toxicity threshold.

Subtype B — Primary Calcium Channelopathy Leading to Multi-System Failure

Calcium dysfunction is upstream. The TRPM3 channelopathy is the root lesion; energy failure, immune dysfunction, and potentially sleep disruption are all downstream consequences. In this subtype:

TRPM3 dysfunction impairs Ca²⁺ transients required for mitochondrial activation
Insufficient Ca²⁺ signaling reduces ATP synthesis capacity under demand (the Calcium-Mitochondria Cascade Hypothesis, Section Novel Hypotheses from TRPM3 Ion Channel Research)
Impaired NK cell degranulation permits viral persistence, sustaining inflammatory burden
Potential systemic TRPM3 dysfunction in sensory neurons, vascular smooth muscle, and brain tissue creates the full multi-system phenotype

Treating the mitochondria in Subtype B addresses consequences but not cause; restoring TRPM3 function would be causal.

The Diagnostic Problem

These two subtypes may be clinically indistinguishable at presentation. Both produce fatigue, PEM, and immune dysfunction. Key differentiating questions: Does the calcium problem precede or follow the energy failure? Is TRPM3 dysfunction detectable before the metabolic crisis, or only during PEM? Current cross-sectional TRPM3 assays cannot answer this — prospective longitudinal studies with paired TRPM3 + metabolic measurements are needed.

Overlap and Mixed Subtypes

The subtypes are not mutually exclusive. A patient could have primary TRPM3 channelopathy (Subtype B) that impairs mitochondrial function, which then triggers secondary NCX reversal during exertion (Subtype A component), creating a self-amplifying cascade. In such patients, both MDC002 (prevents NCX reversal) and TRPM3 restoration (addresses root cause) might be needed.

(Certainty: 0.35. The Subtype A/B framework is a proposed organizing structure not yet published in peer-reviewed literature as a formal taxonomy. The individual mechanisms it groups are supported by evidence; the unification is conceptual. Not yet tested as a subtyping framework.)

10 Subtyping Implications

The TRPM3 findings may help define ME/CFS subgroups:

TRPM3-positive ME/CFS: Measurable TRPM3 dysfunction; potentially responsive to ion channel modulators; may represent the “post-infectious channelopathy” subtype
TRPM3-negative ME/CFS: Normal TRPM3 function; different underlying mechanism; may require different therapeutic approach
TRPM3 + autoantibody positive: Combined channelopathy and autoimmune; may need immunomodulation plus channel restoration
TRPM3-positive but autoantibody-negative: Primary ion channel pathology; direct channel therapy may suffice

This parallels the evolution of cancer treatment—from “breast cancer” to “HER2-positive breast cancer” with targeted therapy. ME/CFS may similarly fragment into molecular subtypes with tailored treatments.

11 TRPM3 and TRPM7 Dual Channelopathy

Hypothesis: Dual TRPM3+TRPM7 Dysfunction as a Subtype-Defining Signature

TRPM3 dysfunction is well-replicated across six cohort studies (2017–2026). Du Preez et al. (2023) extended this to TRPM7, demonstrating significantly reduced TRPM7-dependent Ca²⁺ influx slope in ME/CFS NK cells (n=9) (Preez et al. 2023). TRPM7 is a chanzyme — a fused ion channel and kinase — that regulates intracellular Mg²⁺ homeostasis, cell migration, and apoptotic cell clearance through phosphorylation of annexin A1 and myosin IIA. These substrates are required for immune cell motility and phagocytic function.

Proposed mechanism: When both TRPM3 (Ca²⁺ entry for degranulation) and TRPM7 (Mg²⁺ homeostasis and immune cell motility) are dysfunctional simultaneously, NK cells face a compounded functional deficit: they are unable to migrate efficiently to target cells AND unable to complete degranulation upon arrival. The functional impairment is predicted to exceed what either channelopathy alone would produce.

Subtype-defining implication: Patients with dual TRPM3+TRPM7 dysfunction may represent a more severe immune channelopathy subtype. The number of dysfunctional TRP channels could serve as a dimensional severity measure rather than a binary biomarker.

Falsifiable prediction: ME/CFS patients with simultaneous TRPM3 and TRPM7 dysfunction (measured by patch-clamp Ca²⁺ flux in NK cells) should show worse NK cytotoxicity than patients with TRPM3 dysfunction alone. Bell scale functional scores should correlate inversely with the number of dysfunctional TRP channels. (Certainty: 0.42. TRPM3 dysfunction replicated; TRPM7 finding is single study, n=9, not independently replicated.)

12 PIP₂ Depletion as the Convergence Mechanism

Hypothesis: PIP₂ Exhaustion Links GPCR Autoantibodies to Multi-Channel Dysfunction

Eaton-Fitch et al. (2021) demonstrated reduced TRPM3/PIP₂ co-localization in ME/CFS NK cells (Eaton-Fitch et al. 2021). PIP₂ (phosphatidylinositol 4,5-bisphosphate) is a plasma membrane phospholipid required for the gating of multiple ion channel families including TRPM3, TRPM7, Piezo channels, and KCNQ potassium channels. PIP₂ is consumed by phospholipase C (PLC) downstream of GPCR signaling.

Proposed convergence mechanism: Chronic stimulation of GPCR autoantibodies (anti-\(\beta_2\)-adrenergic, anti-muscarinic M3/M4) documented in ME/CFS tonically activates PLC, consuming PIP₂ faster than PI4K/PIP5K enzymes can regenerate it. The resulting PIP₂ pool depletion simultaneously impairs:

TRPM3 gating → reduced Ca²⁺ entry for NK degranulation
TRPM7 gating → Mg²⁺ homeostasis disrupted
Piezo channel mechanosensitivity → altered RBC deformability and mechanosensing
KCNQ channel function → altered neuronal and cardiac excitability

This mechanism transforms the GPCR autoantibody hypothesis and the TRPM3 channelopathy hypothesis from parallel independent findings into a single upstream deficit. A chronic PIP₂ supply problem simultaneously explains why multiple ion channel families are dysfunctional in the same patients.

Falsifiable predictions: (a) PIP₂ levels in ME/CFS NK cell membranes (measured by anti-PIP₂ immunofluorescence or membrane phosphoinositide mass spectrometry) should be reduced compared to healthy controls. (b) In vitro PIP₂ supplementation (exogenous diC8-PIP₂) should partially rescue TRPM3-mediated Ca²⁺ flux in ME/CFS cells even without naltrexone. (c) GPCR autoantibody titers should inversely correlate with membrane PIP₂ levels across ME/CFS patients.

(Certainty: 0.45. The PIP₂/TRPM3 co-localization deficit is a direct experimental finding; the GPCR → PLC → PIP₂ cascade is established signaling biology; the convergence as a unified mechanism is inferred, not demonstrated. Not yet replicated.)

Intersection with low-dose lithium: Li⁺ inhibits IMPase/IMPA1, the enzyme regenerating free inositol for PIP₂ resynthesis, and disrupts the NCS-1/InsP3R1 interaction that amplifies IP3-mediated Ca²⁺ release. These actions directly impinge on the PIP₂ supply problem described here — see Lithium Safety: Drug Interactions and Contraindications for mechanistic detail and certainty assessment.

13 PLC-Delta Positive Feedback and Self-Sustaining PIP₂ Depletion

Speculation: PLC-delta Positive Feedback Loop: PIP₂ Depletion as a Self-Sustaining State

PLC exists in multiple isoforms with distinct activation mechanisms: PLC-\(\beta\) is activated by G-protein-coupled receptors (the GPCR autoantibody route described in PIP₂ Exhaustion Links GPCR Autoantibodies to Multi-Channel Dysfunction), while PLC-\(\delta\) is activated by elevated cytosolic Ca²⁺ itself. If GPCR autoantibody-driven PLC-\(\beta\) activity raises cytosolic calcium, this elevation may activate PLC-\(\delta\) independently, generating a self-amplifying cycle: elevated Ca²⁺ → PLC-\(\delta\) activation → PIP₂ cleavage → more IP3 → more ER Ca²⁺ release → more cytosolic Ca²⁺.

If this positive feedback loop becomes autonomous, PIP₂ depletion would persist even after autoantibody removal. This could explain why immunoadsorption and BC007 therapy produce inconsistent or partial responses in some patients: by the time the autoantibodies are cleared, the PLC-\(\delta\) feedback loop may have become self-sustaining at a level independent of GPCR stimulation.

Falsifiable predictions. (a) PLC-\(\delta\) expression or activity is elevated in ME/CFS cells relative to healthy controls. (b) PLC-\(\delta\) inhibition (e.g., compound U73122 in vitro, or calcium chelation) allows PIP₂ to recover even without removal of GPCR autoantibodies. (c) ME/CFS patients with residual PIP₂ depletion after successful autoantibody clearance show higher PLC-\(\delta\) activity than those who fully recover.

(Certainty: 0.15. PLC-\(\delta\) calcium activation is established cell biology; its role in sustaining ME/CFS pathology is entirely inferred. No ME/CFS-specific data on PLC isoforms exist. Not yet replicated.)

14 Store-Operated Calcium Entry and Futile Cycling

Speculation: Futile ER Calcium Cycling via STIM1/Orai1 in ME/CFS

When ER calcium stores are depleted by chronic IP3-driven release, STIM1 proteins in the ER membrane oligomerize and translocate to ER–plasma membrane junctions, activating Orai1 channels to trigger store-operated calcium entry (SOCE). This is the cell’s homeostatic refilling response. In a context of chronic GPCR autoantibody-driven IP3 generation, however, SOCE may enter a futile cycle: calcium imported via Orai1 is pumped into the ER by SERCA (consuming 1 ATP per 2 Ca²⁺ ions transported), only to be immediately released again by ongoing IP3R activation, before SERCA can complete refilling. The net result is continuous SOCE activation, elevated cytosolic calcium, persistent ER Ca²⁺ depletion, and significant ATP consumption with no net restoration of calcium homeostasis.

An additional complication: Orai1 channel activity itself requires PIP₂ for proper gating. In ME/CFS, where membrane PIP₂ is already depleted (PIP₂ Exhaustion Links GPCR Autoantibodies to Multi-Channel Dysfunction), SOCE could be doubly compromised — STIM1 signaling is activated (by ER depletion) but Orai1 cannot respond normally (due to PIP₂ deficiency). The cell would thus be simultaneously unable to restore ER calcium and unable to fully activate the compensatory channel.

Falsifiable predictions. (a) STIM1 puncta formation (an ER–plasma membrane junction marker visible by immunofluorescence) should be elevated in resting ME/CFS cells relative to healthy controls, reflecting chronic ER calcium depletion. (b) Thapsigargin-releasable ER calcium should be reduced in ME/CFS cells (smaller ER calcium pool). (c) SERCA-dependent ATP consumption (oligomycin-sensitive OCR fraction) should be elevated in ME/CFS cells, reflecting futile cycling.

(Certainty: 0.25. Each individual component — SOCE activation, SERCA ATP cost, PIP₂ Orai1 dependence — is established cell biology. The convergence as a futile cycling state in ME/CFS is inferred from the GPCR autoantibody hypothesis; no direct measurement of SOCE activity or STIM1 puncta in ME/CFS cells has been published. Not yet replicated.)

15 ER-to-Mitochondria Calcium Transfer: IP3R/VDAC/MCU Axis

Speculation: Dual-Route Mitochondrial Calcium Overload in ME/CFS: NCX Reversal Plus IP3R/VDAC/MCU

The NCX reversal mechanism (NHE1 → Na⁺ overload → NCX1 reverse mode → cytoplasmic Ca²⁺ import) is described in Calcium Toxicity as the Primary Mechanism of Post-Exertional Malaise as the plasma-membrane route to mitochondrial calcium overload during PEM. A second, simultaneous route operates from the ER side: at mitochondria-associated ER membranes (MAMs), IP3R3 forms physical complexes with VDAC1 on the outer mitochondrial membrane, linked by the chaperone GRP75. Ca²⁺ released from ER via IP3R is preferentially funnelled through VDAC1 into the intermembrane space, then through the mitochondrial calcium uniporter (MCU) into the matrix.

If GPCR autoantibody-driven PLC activation generates chronic IP3 flux, ER calcium release would be elevated. NCS-1 (neuronal calcium sensor protein 1) amplifies IP3R channel open probability approximately five-fold; whether NCS-1 expression is elevated in ME/CFS is unknown, but if so this would further amplify ER Ca²⁺ release (see NCS-1 in ME/CFS: Elevated, Normal, or Reduced? and Lithium Safety: Drug Interactions and Contraindications). The IP3R/GRP75/VDAC1/MCU pathway would then deliver excessive calcium directly to the mitochondrial matrix. This ER-side route is additive with the NCX-reversal route: during PEM, both could operate simultaneously — NCX-reversal from plasma membrane-side sodium overload, AND IP3R/VDAC/MCU from ER-side IP3 excess. The combination would impose greater mitochondrial calcium loading than either mechanism alone, potentially explaining why mitochondrial damage in ME/CFS appears disproportionate to the degree of ischemia.

A further connection: S1R stabilizes IP3R3 at MAMs (Section Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy). If S1R function is impaired in ME/CFS (by viral protein binding, ER stress, or autoimmune disruption), the IP3R3/MAM coupling may become dysregulated, contributing to uncontrolled calcium transfer.

Falsifiable predictions. (a) ME/CFS patient cells should show elevated mitochondrial calcium at baseline, measurable by Rhod-2 AM fluorescence. (b) IP3R inhibition (2-APB or xestospongin C, in vitro) should reduce mitochondrial calcium overload in ME/CFS cells more than in healthy controls. (c) GRP75 expression or IP3R3/VDAC1 co-localization at MAMs should be altered in ME/CFS cells.

(Certainty: 0.30. The IP3R/GRP75/VDAC1/MCU calcium transfer pathway is well-established cell biology. Application to ME/CFS is entirely inferential from the PIP₂ exhaustion and GPCR autoantibody hypotheses. No direct MAM or MCU measurements in ME/CFS tissue exist. Not yet replicated.)

16 The Expanded TRP Channel Sensitization Hypothesis

Speculation: Beyond TRPM3: A Broader TRP Channelopathy in ME/CFS?

TRPM3 dysfunction has been replicated in independent cohorts in ME/CFS (Helene Cabanas et al. 2021) (Sasso et al. 2026). Extending beyond TRPM3, du Preez et al. (2023) demonstrated that TRPM7-dependent Ca²⁺ influx slope is also significantly reduced in ME/CFS NK cells following TRPM7 activation (n=9, not yet independently replicated) (Preez et al. 2023) — raising the possibility that the channelopathy is not limited to TRPM3 but reflects a broader dysfunction across the TRP channel family. TRPM3 belongs to the TRP superfamily alongside TRPV1 (vanilloid 1) and TRPA1 (ankyrin 1), which are co-expressed in sensory neurons, mast cells, and Schwann cells. TRPV1 is described as a “molecular integrator of noxious stimuli” based on its polymodal activation properties: it responds to heat >43°C, capsaicin, protons (pH below 6), and prostaglandins, and is sensitized by PGE₂ via EP1 and IP receptors (Moriyama et al. 2005). TRPA1 functions as an oxidative stress sensor, activated by H₂O₂, acrolein, and electrophilic tissue damage metabolites through covalent modification of reactive cytosolic cysteines (Macpherson et al. 2007).

Proposed mechanism:

In ME/CFS, elevated systemic ROS and chronic prostaglandin production sensitize both TRPV1 and TRPA1 on sensory neurons and mast cells
Sensitized TRPV1 creates a feed-forward loop: activation upregulates COX2 in sensory neurons, generating more prostaglandins, which re-sensitize TRPV1 (Li et al. 2021)
Sensitized TRPA1 on Schwann cells sustains neurogenic inflammation independently of axonal injury
TRPV1-mast cell axis: capsaicin-induced activation of TRPV1 on dural mast cells triggers degranulation via non-IgE neurogenic pathway in rodent models (Costa et al. 2024); whether this mechanism operates in human peripheral sensory mast cells is not yet directly demonstrated
Multiple chemical sensitivity (MCS) in ME/CFS patients may represent TRP sensitization reducing activation threshold to sub-ordinary chemical concentrations (Molot, Sears, and Anisman 2023)

Whether TRPV1 and TRPA1 dysfunction co-occurs with TRPM3 dysfunction in ME/CFS is not yet tested. However, shared expression patterns in sensory neurons and the common oxidative stress milieu of ME/CFS provide a plausible mechanism for concurrent multi-TRP-channel sensitization.

Testable predictions.

ME/CFS patients with MCS features should show lower capsaicin-induced flare thresholds than ME/CFS patients without chemical sensitivity (TRPV1 sensitization)
TRPA1 activation threshold (measured by allyl isothiocyanate/mustard challenge) should be reduced in ME/CFS patients with elevated oxidative stress markers
NK cells from ME/CFS patients (already showing TRPM3 dysfunction) should also show altered TRPV1/TRPA1 gating properties
ME/CFS patients with elevated pain/MCS features treated with TRPV1 antagonists should show reduced capsaicin-evoked flare responses (objective TRPV1 sensitization endpoint), not merely self-reported symptom improvement

(Certainty: 0.40. TRPM3 dysfunction is replicated; TRPV1/TRPA1 co-sensitization in ME/CFS is mechanistically plausible but not yet directly tested. Not yet replicated in ME/CFS.)

17 TRP-Targeted Therapeutic Approaches: Ambroxol as TRPV1 Antagonist

Speculation: Ambroxol as a Repurposed TRP Channel Modulator in ME/CFS

Ambroxol is an OTC mucolytic (active metabolite of bromhexine) with two distinct analgesic mechanisms identified in preclinical and electrophysiological studies: preferential block of Nav1.8 voltage-gated sodium channels in nociceptors (Gaida et al. 2005), and direct inhibition of TRPV1-mediated calcium influx demonstrated by patch-clamp electrophysiology on human TRPV1 channels (Hefner et al. 2025).

Mechanistic rationale for ME/CFS:

If TRPV1 sensitization contributes to ME/CFS pain and chemical hypersensitivity (as proposed above Beyond TRPM3: A Broader TRP Channelopathy in ME/CFS?), ambroxol’s TRPV1 antagonism could theoretically reduce sensitization-driven nociceptor activation
Nav1.8 block would additionally reduce action potential firing in small-diameter pain-sensing fibers independently of upstream sensitization
Ambroxol also modulates TRPA1 at higher concentrations (Hefner et al. 2025), potentially addressing oxidative-stress-driven TRPA1 activation

Available evidence:

Preclinical: Effective in rat neuropathic and inflammatory pain models; exceeds gabapentin efficacy at clinically achievable doses (Gaida et al. 2005)
Electrophysiology (2025): hTRPV1 antagonism reported by patch-clamp (partly reversible; single lab, not independently replicated); study context is topical neuropathic pain — tissue concentrations with topical application are far higher than systemic oral plasma levels (Hefner et al. 2025)
Clinical: Case series report pain reduction in trigeminal neuralgia, fibromyalgia, and CRPS at 75–300 mg/day; no serious adverse effects (Russo et al. 2023)
No clinical trials in ME/CFS or post-exertional neuropathic pain

Translational caveats:

Nav1.8 species-specificity: rat IC₅₀ 18 µM vs human IC₅₀ 279 µM; rodent efficacy data may overestimate human analgesic effect via Nav1.8 block alone (Hefner et al. 2025)
TRPV1 antagonism is shown on human channels but optimal systemic concentrations for ME/CFS pain are not established
All clinical data are case series or small uncontrolled studies; no RCTs in any neuropathic pain indication as of the 2023 review (Russo et al. 2023)

Testable prediction:

ME/CFS patients with elevated pain and MCS features should show measurable pain reduction with oral ambroxol 75–150 mg/day; effect should correlate with capsaicin flare-threshold improvement (TRPV1 endpoint)

(Certainty: 0.35. Mechanism established in general pain pharmacology; ME/CFS-specific application is entirely extrapolated. Not yet replicated in ME/CFS.)

18 TRP Channel Pentamerization: A Structural Escalation Mechanism

Speculation: TRP Pentamer Formation as a Gain-of-Function Escalation in ME/CFS

TRP channels are canonically tetramers — four subunits assembling around a central ion-conducting pore. In 2023, Lansky et al. used high-speed atomic force microscopy (HS-AFM) combined with cryo-EM to demonstrate that TRPV3 channels transition from tetramers to pentamers under sustained agonist exposure, via membrane-diffusive protomer exchange (Lansky et al. 2023). The pentameric pore is approximately 2.4-fold wider than the tetrameric pore, with a lifetime of approximately 3 minutes, and is promoted by prolonged agonist application. A subsequent study from the same group (2025) resolved the pentameric structure at 4.07 Å by cryo-EM and performed molecular dynamics simulations confirming that the pentameric selectivity filter is 5.3-fold wider and the gate 7.3-fold wider than the closed tetramer, permitting free passage of large organic cations (Tris⁺, NMDG⁺, 2-MAE⁺) that are excluded by the tetramer (Lansky et al. 2025). Multiple structurally diverse agonists (2-APB, camphor, propofol) destabilize tetramers and facilitate pentamer formation, and the authors describe the pentameric state as “hyper-activated.” Ren et al. (2024) proposed oligomeric stoichiometry switching as a general gating mechanism across ion channel families, suggesting it may extend beyond TRPV3 (Ren, Yang, and Shen 2024).

Proposed ME/CFS relevance: If sustained pathological stimulation of TRP channels in ME/CFS — driven by chronic oxidative stress, elevated prostaglandins, or inflammatory lipids (Section Beyond TRPM3: A Broader TRP Channelopathy in ME/CFS?) — promotes tetramer-to-pentamer transition, the result would be a qualitative shift from modulated ion flux to uncontrolled ionic leak. This represents a fundamentally different state from simple loss-of-function or gain-of-function gating: a structural rearrangement producing a hyper-conductive pore that admits ions and molecules normally excluded.

In a feedforward loop context: sensitized TRPV1 (by PGE₂) or TRPA1 (by ROS) → prolonged activation → protomer exchange → pentamer formation → dramatically amplified Ca²⁺ influx → further inflammatory mediator release → further TRP activation. The 3-minute pentamer lifetime is sufficient to trigger sustained downstream calcium signaling cascades. If pentamer formation probability increases with each activation episode, disease progression would show a ratchet-like escalation — each PEM episode or inflammatory flare driving a larger fraction of channels into the hyper-activated pentameric state.

Critical limitation: Pentamer formation has been demonstrated only for TRPV3. Whether TRPM3, TRPV1, or TRPA1 undergo analogous stoichiometry transitions is unknown. The TRPV3 pentamer discovery is recent (2023) and independently replicated only by the same laboratory (Lansky/Scheuring group). Extrapolation to other TRP family members, and to ME/CFS pathophysiology specifically, is entirely inferential. No ME/CFS study has examined TRP channel stoichiometry in patient cells.

Falsifiable predictions. (a) TRPV3 (and potentially TRPV1) channels in ME/CFS patient sensory neurons or immune cells should show elevated pentamer:tetramer ratios relative to healthy controls, measurable by single-molecule imaging or native gel electrophoresis. (b) Pharmacological stabilization of the tetrameric state (if such compounds are identified) should reduce TRP-mediated calcium flux in ME/CFS cells. (c) Pentamer formation frequency should correlate with disease severity or duration, reflecting cumulative inflammatory exposure.

(Certainty: 0.20. TRPV3 pentamerization is established structural biology; extension to TRPM3 or other TRP channels is undemonstrated; application to ME/CFS is a double extrapolation. Not yet studied in ME/CFS.)

Speculation: PIP₂ Depletion Lowers the Pentamerization Threshold

PIP₂ stabilizes TRP channels in their closed or low-conductance tetrameric conformations. The PIP₂ depletion mechanism described in Section PIP₂ Exhaustion Links GPCR Autoantibodies to Multi-Channel Dysfunction — where GPCR autoantibody-driven PLC-\(\beta\) activity chronically consumes PIP₂ — may create a constitutive predisposition to pentamer formation. If PIP₂ depletion destabilizes the tetrameric closed state, then a lower concentration of agonist would suffice to trigger protomer exchange and pentamer assembly. The chain: GPCR autoantibodies → PLC-\(\beta\) → PIP₂ consumption → loss of tetrameric stabilization → lower barrier to pentamer transition → hyper-conductive pore at sub-threshold stimuli → calcium overload → PLC-\(\delta\) activation (Section PLC-delta Positive Feedback Loop: PIP₂ Depletion as a Self-Sustaining State) → further PIP₂ depletion.

This would mean ME/CFS patients’ TRP channels are constitutively closer to the pentamerization threshold than healthy channels, even before an exertion trigger. Every inflammatory episode or PEM event would push more channels across a lowered threshold.

Falsifiable prediction. In vitro, PIP₂ depletion (using a synthetic PIP₂ phosphatase or PLC activators) should increase TRPV3 pentamer frequency measurable by HS-AFM. ME/CFS cells with documented PIP₂ depletion should show higher pentamer fractions than PIP₂-replete cells from the same patients after exogenous diC8-PIP₂ supplementation.

(Certainty: 0.15. PIP₂’s role in TRP channel gating is established; that PIP₂ depletion specifically facilitates pentamer formation is inferred, not demonstrated. Not yet studied.)

The pentameric pore has implications beyond calcium flux. Lansky et al. (2025) demonstrated that the pentameric channel admits large organic cations — Tris⁺ (MW 121), NMDG⁺ (MW 195), 2-MAE⁺ — that tetrameric channels exclude (Lansky et al. 2025). If pentamerization occurs in ME/CFS, this represents a loss of membrane molecular selectivity, not merely increased ion flux. Pentamerized channels could theoretically admit polyamines (spermine, spermidine) or other normally membrane-impermeant molecules, potentially disrupting intracellular signaling through mechanisms entirely distinct from calcium overload. This “molecular sieve failure” is highly speculative (certainty: 0.10) and would require demonstration that pentameric TRP channels in vivo admit specific pathologically relevant molecules.

If pentamer formation probability increases cumulatively with each inflammatory episode, the pentamer:tetramer ratio could serve as a molecular record of cumulative disease burden. This “pentamer ratchet” predicts that the ratio should correlate with disease duration (not just current severity), with patients of longer duration showing higher pentamer fractions at matched severity levels. This would be testable by native gel electrophoresis of TRP channels from PBMCs stratified by disease duration.

19 Arteriolar TRPV1 and PEM-Associated Vasoconstriction

Hypothesis: TRPV1 in Vascular Smooth Muscle as a Mechanism for PEM-Associated Perfusion Failure

TRPV1 expression is not restricted to sensory neurons. Using TRPV1-reporter mice and cross-species histology, Cavanaugh et al. (2011, Julius/Basbaum group) demonstrated functional TRPV1 expression in arteriolar smooth muscle cells across thermoregulatory tissues (cremaster, dura, tongue, trachea, skin), where capsaicin activation caused calcium influx and vasoconstriction — the opposite of the vasodilation mediated by neuronal TRPV1 (Cavanaugh et al. 2011).

Phan et al. (2020) extended this finding to terminal arterioles in skeletal muscle, heart, and adipose tissue. TRPV1 activation in these resistance arterioles produced sustained vasoconstriction and elevated blood pressure that persisted after complete nerve ablation, confirming a vascular-intrinsic (non-neuronal) mechanism. Critically, arteriolar TRPV1 was resistant to desensitization — unlike neuronal TRPV1, which rapidly desensitizes upon prolonged capsaicin exposure. The mechanism operates through TRPV1 membrane depolarization → L-type Ca²⁺ channel activation → sustained smooth muscle contraction (Phan et al. 2020). Lysophosphatidic acid (LPA), an inflammatory lipid generated during tissue damage, was identified as an endogenous activator.

Phan et al. (2022) further demonstrated that TRPV1 drives rapid myogenic tone in cardiac and skeletal muscle arterioles via PLC/PKC signaling. TRPV1 antagonists dilated arterioles and increased coronary flow, while TRPM4 contributed the remaining tone. TRPV1 disruption also impaired post-constriction vasodilatory recovery (Phan et al. 2022).

Important tissue specificity nuance: Rivera-Mancilla et al. (2024) examined human dermal arteries ex vivo and found that TRPV1 and TRPA1 did not activate standard vasodilation pathways in this tissue bed, while TRPM3 (activated by pregnenolone sulfate) produced relaxation via non-CGRP mechanisms (Rivera-Mancilla et al. 2024). This demonstrates that TRP-mediated vascular effects are tissue-bed-specific: skeletal muscle resistance arterioles (Phan data) and dermal arteries (Rivera-Mancilla data) respond differently.

Proposed PEM mechanism: During physical exertion in ME/CFS patients:

Exercise-induced micro-damage generates LPA and oxidized phospholipids in skeletal muscle
These endogenous ligands activate arteriolar TRPV1 in skeletal muscle resistance arterioles
TRPV1 activation → L-type Ca²⁺ channel → sustained vasoconstriction
Non-desensitizing nature of arteriolar TRPV1 enables prolonged abnormal vascular tone
Sustained vasoconstriction → impaired oxygen and substrate delivery during and after exertion
Compounded by: TRPM3-mediated vascular relaxation failure (Beyond TRPM3: A Broader TRP Channelopathy in ME/CFS?; (Rivera-Mancilla et al. 2024)) and stiffened RBCs (Section Piezo1 Dysregulation as a Mechanism for RBC Stiffness in ME/CFS)
The delayed and prolonged nature of PEM (12–72 hours post-exertion) is consistent with LPA generation kinetics following tissue micro-damage

This mechanism addresses a gap in current PEM models: why perfusion failure persists long after exertion has ceased. NCX reversal (Highly Speculative Therapeutics, Subtype A) explains the immediate sodium/calcium crisis, but the vascular component — why arteriolar tone remains elevated — has lacked a molecular anchor. Arteriolar TRPV1, activated by exercise-generated inflammatory lipids and resistant to desensitization, provides this anchor.

Falsifiable predictions. (a) TRPV1 expression in skeletal muscle arterioles from ME/CFS patients (skin punch biopsy with microvascular analysis, or post-mortem tissue) should be detectable and potentially upregulated relative to healthy controls. (b) TRPV1 antagonists (AMG 517, SB-705498 — research tools) should attenuate exercise-induced perfusion reduction in ME/CFS patients, measurable by near-infrared spectroscopy (NIRS) or contrast-enhanced ultrasound of muscle microcirculation. (c) Plasma LPA levels should be elevated post-exercise in ME/CFS patients relative to healthy controls, and should correlate with PEM severity. (d) TRPV1 antagonism should not affect PEM severity in patients whose PEM is primarily metabolic (Subtype A dominant per Section Two-Test Protocol for Subtype A vs Subtype B Classification) rather than vascular.

(Certainty: 0.40. Arteriolar TRPV1 expression and non-desensitizing vasoconstriction are established in rodent models (two independent groups: Julius/Basbaum and Ahern). LPA as endogenous activator is demonstrated. Application to ME/CFS PEM is entirely inferential — no ME/CFS vascular TRPV1 data exist. Tissue specificity (Rivera-Mancilla 2024 dermal vs Phan skeletal muscle) remains an open question for human tissue. Not yet studied in ME/CFS.)

A critical feature of the arteriolar TRPV1 mechanism is its dissociation from neuronal TRPV1. Cavanaugh et al. (2011) showed that neuronal and arteriolar TRPV1 produce opposite vascular effects: neuronal TRPV1 activation causes vasodilation (via CGRP release from afferents), while arteriolar TRPV1 activation causes vasoconstriction (Cavanaugh et al. 2011). In ME/CFS with sensitized TRPV1, this creates a “dual trap”: nociceptive TRPV1 signals pain (telling the patient to stop exerting) while arteriolar TRPV1 maintains vasoconstriction (preventing perfusion recovery even at rest). The non-desensitizing nature of arteriolar TRPV1 (Phan et al. 2020) means that even if neuronal TRPV1 partially habituates (reducing pain perception), the vascular arm continues to restrict perfusion. This dissociation could explain why some patients report that pain diminishes before fatigue does — the nociceptive warning system adapts while the vascular damage persists.

Speculation: Two-Compartment PEM Cascade: NCX Reversal Plus Arteriolar TRPV1

The NCX reversal mechanism (Section Highly Speculative Therapeutics, Subtype A: NHE1 → Na⁺ overload → NCX1 reverse mode → Ca²⁺ import) and the arteriolar TRPV1 mechanism are not independent — they are coupled through tissue ischemia. In the first phase (0–2 hours post-exertion), both mechanisms activate simultaneously: proton accumulation drives NCX reversal in muscle cells, while exercise-generated LPA activates arteriolar TRPV1. In the second phase (2–24 hours), the two arms reinforce each other: TRPV1-mediated vasoconstriction reduces oxygen delivery, which prevents Na⁺/K⁺-ATPase recovery (ATP-dependent), maintaining NCX in reverse mode. Sustained NCX reversal generates continued calcium overload, which activates PLC-\(\delta\) (Section PLC-delta Positive Feedback Loop: PIP₂ Depletion as a Self-Sustaining State), depleting PIP₂ and potentially facilitating TRP pentamerization (Section PIP₂ Depletion Lowers the Pentamerization Threshold). In the third phase (24–72 hours), slow LPA clearance (tissue half-life measured in hours to days) maintains vasoconstriction, while mitochondrial damage from calcium overload reduces ATP capacity, lowering the exertion threshold for the next episode.

Treating only one arm may be insufficient: calcium channel blockers (for NCX reversal) cannot restore perfusion if TRPV1-mediated vasoconstriction persists; conversely, TRPV1 antagonists cannot prevent calcium overload if NCX reversal continues.

Falsifiable prediction. Combined treatment targeting both arms (e.g., NCX modulator + TRPV1 antagonist) should reduce PEM duration more than either alone. Measurable by sequential NIRS (perfusion arm) and ²³Na-MRI (NCX arm) at 24 hours post-standardized exercise.

(Certainty: 0.35. Each arm is supported by independent evidence; the coupling through ischemia is inferred but mechanistically coherent. Not yet studied as a combined model.)

Speculation: LPA–Microclot–TRPV1 Triangle: Three Vascular Pathologies Converging

Microclots documented in ME/CFS (Chapter Cardiovascular Dysfunction, Section Vascular Dysfunction) cause capillary obstruction and downstream tissue ischemia. Ischemic tissue activates phospholipase A2, generating LPA. LPA activates arteriolar TRPV1 (TRPV1 in Vascular Smooth Muscle as a Mechanism for PEM-Associated Perfusion Failure), causing vasoconstriction upstream of the microclot obstruction, compounding the perfusion deficit. Additionally, TRPV1-mediated vasoconstriction alters local flow dynamics — increased wall shear stress at constriction points and turbulent flow downstream may promote further fibrin deposition and microclot formation. This creates a three-way positive feedback: microclots → ischemia → LPA → TRPV1 vasoconstriction → altered flow → more microclots.

This triangle connects two previously separate pathological domains in ME/CFS (coagulation and TRP channelopathy) through a specific molecular intermediary (LPA) that is measurable and targetable. Autotaxin inhibitors (ziritaxestat, in Phase III trials for idiopathic pulmonary fibrosis) or secreted PLA₂ inhibitors (varespladib) would reduce tissue LPA generation, potentially breaking the triangle at the LPA node.

Falsifiable prediction. ME/CFS patients post-exercise should show simultaneous elevation of plasma LPA (LC-MS/MS), D-dimer (microclot turnover marker), and reduced muscle oxygenation (NIRS). Anticoagulation sufficient to reduce microclot burden should partially attenuate post-exercise LPA elevation.

(Certainty: 0.30. Each vertex of the triangle is supported by independent evidence: microclots in ME/CFS, LPA generation from ischemia, TRPV1-mediated vasoconstriction from LPA. The three-way coupling is inferred. Not yet studied as a system.)

Speculation: Mast Cell–TRPV1 Dual Amplification Loop

Mast cell activation in ME/CFS (Chapter Immune System Dysfunction, Section Connections to Allergies and Mast Cell Activation) and arteriolar TRPV1 vasoconstriction converge in a tissue-level positive feedback. Mast cell degranulation releases histamine, tryptase, and prostaglandins. Prostaglandins sensitize both neuronal TRPV1 (via PGE₂/EP1, as described in Section Beyond TRPM3: A Broader TRP Channelopathy in ME/CFS? (Moriyama et al. 2005)) and arteriolar TRPV1. Sensitized arteriolar TRPV1 drives vasoconstriction, producing tissue ischemia. Tissue ischemia activates mast cells (hypoxia-driven degranulation is documented in the mast cell literature), completing the loop.

This creates a local, self-sustaining inflammatory circuit that does not require systemic immune activation. It could explain why ME/CFS symptoms are often regional or patchy rather than uniform — individual tissue beds may or may not have entered the mast cell–TRPV1 feedback state depending on local inflammatory history. Combined mast cell stabilization (ketotifen, cromolyn) plus TRPV1 modulation (ambroxol, Section Ambroxol as a Repurposed TRP Channel Modulator in ME/CFS) would break the loop at two points simultaneously.

Falsifiable prediction. Mast cell stabilizers (cromolyn, ketotifen) should reduce not only allergic symptoms but also exercise-induced vasoconstriction (measurable by NIRS). The combination of ketotifen + ambroxol should be synergistic for PEM reduction compared to either alone.

(Certainty: 0.25. Each component — mast cell activation in ME/CFS, prostaglandin-mediated TRPV1 sensitization, arteriolar TRPV1 vasoconstriction — is independently supported. The closed-loop coupling is inferred. Not yet studied in ME/CFS.)

20 TRP Family as a Coordinated Sensory System

The preceding sections have discussed individual TRP channels (TRPM3, TRPV1, TRPA1, TRPV3) as separate entities. However, the TRP superfamily comprises at least 28 members in mammals grouped into six subfamilies (TRPC, TRPV, TRPM, TRPA, TRPP, TRPML), many of which are co-expressed in the same cell types and share regulatory mechanisms including PIP₂ dependence, redox sensitivity, and calcium-dependent modulation (Delmas and Coste 2020). In sensory neurons, TRPV1, TRPA1, TRPM3, and TRPM8 form overlapping detection arrays for temperature, chemical irritants, oxidative stress, and mechanical stimuli.

In the context of ME/CFS, where chronic inflammation, oxidative stress, and PIP₂ depletion (PIP₂ Exhaustion Links GPCR Autoantibodies to Multi-Channel Dysfunction) simultaneously affect multiple TRP-dependent regulatory mechanisms, the dysfunction may not be limited to one or two channels but may represent a coordinated system-level failure. The relevant question is not “which TRP channel is dysfunctional?” but “how many TRP-dependent regulatory loops have shifted to pathological operating points?” The multi-parameter biomarker panel proposed in Section Piezo2 and Tactile Hypersensitivity in ME/CFS captures this logic by measuring TRPM3 and TRPM7 simultaneously; extending it to include TRPV1 sensitivity (capsaicin flare threshold) and TRPA1 reactivity (allyl isothiocyanate challenge) would test the broader coordinated-failure hypothesis.

Speculation: Tissue-Specific TRP Response Map: One Channelopathy, Many Phenotypes

The tissue specificity demonstrated by Rivera-Mancilla et al. (2024) — TRPM3 relaxes dermal arteries while TRPV1 constricts skeletal muscle arterioles (Rivera-Mancilla et al. 2024) — implies that a single systemic TRP channelopathy could produce opposite effects depending on tissue bed. This provides a parsimonious explanation for the multi-system nature of ME/CFS without requiring separate pathological mechanisms for each symptom domain:

Predicted tissue-specific manifestations of systemic TRP channelopathy in ME/CFS. The dominant TRP channel in each tissue determines the local phenotype of a shared upstream dysfunction.
Tissue	Dominant TRP	Predicted dysfunction
Skeletal muscle arterioles	TRPV1	Vasoconstriction → exercise intolerance, PEM
Dermal arteries	TRPM3	Impaired relaxation → Raynaud’s-like symptoms
Cardiac arterioles	TRPV1 + TRPM4	Vasoconstriction → reduced cardiac output
Sensory neurons	TRPV1/TRPA1/TRPM3	Sensitization → pain, MCS, hyperalgesia
NK cells	TRPM3	Impaired Ca²⁺ flux → failed degranulation
Cerebral arterioles	Unknown (likely mixed)	Perfusion instability → cognitive dysfunction

The tissue-specific response profile should predict which symptom domains predominate in individual patients. Patients with primarily vascular symptoms (POTS, exercise intolerance) would show greater arteriolar TRPV1 dysfunction, while patients with primarily immune symptoms (infections, lymphadenopathy) would show predominantly TRPM3 dysfunction. This converts the systemic channelopathy hypothesis from a qualitative concept to a quantitatively testable framework.

(Certainty: 0.35. Tissue-specific TRP vascular responses are demonstrated for two tissue beds. Extrapolation to all listed tissues is inferred. Not yet studied as a diagnostic framework.)

21 Cross-Disease Bridges: TRP Channel Parallels

The TRP channelopathy framework connects ME/CFS to several other conditions through shared molecular mechanisms:

Erythromelalgia involves Nav1.7 gain-of-function mutations producing excessive vasodilation and burning pain — a mirror image of the arteriolar TRPV1-mediated vasoconstriction proposed here. If confirmed, TRPV1 antagonists effective in ME/CFS would be predicted to worsen erythromelalgia symptoms (opposite direction on the ion channel → vascular tone axis).

Fibromyalgia may represent primarily neuronal TRP sensitization (TRPV1/TRPA1 on nociceptors) without the vascular and immune components of ME/CFS. This would predict: fibromyalgia-only patients should have normal exercise-induced muscle perfusion (NIRS) despite elevated pain; ME/CFS-only patients should show impaired perfusion; and overlap patients should exhibit both.

Sickle cell vaso-occlusive crises share key elements with the LPA–microclot–TRPV1 triangle: microvascular obstruction, ischemia-driven LPA generation, and TRPV1-mediated pain. Recent preclinical work demonstrates that TRPV1 antagonists reduce vaso-occlusive crisis severity in mouse models. If confirmed in human trials, the same TRPV1 antagonists would be candidates for ME/CFS PEM — the shared LPA-driven mechanism predicts similar responses.

Migraine involves TRPV1 on trigeminal neurons, CGRP release, and high comorbidity with ME/CFS. If TRP pentamerization occurs during prolonged trigeminal activation in migraine aura, ME/CFS patients with comorbid migraine might show higher TRP pentamer fractions than those without, reflecting greater cumulative inflammatory TRP exposure. The pentameric pore’s ability to admit large organic cations (Section TRP Pentamer Formation as a Gain-of-Function Escalation in ME/CFS) could contribute to CGRP-independent migraine mechanisms.

22 TRP-Targeted Therapeutic Extensions

The arteriolar TRPV1 mechanism and LPA–microclot triangle suggest several therapeutic approaches beyond those discussed in the ambroxol section (Ambroxol as a Repurposed TRP Channel Modulator in ME/CFS):

Speculation: NEO6860: Next-Generation TRPV1 Antagonist Without Hyperthermia Risk

Early TRPV1 antagonists (AMG 517) caused dangerous hyperthermia by blocking TRPV1’s thermoregulatory function. NEO6860 is a next-generation selective TRPV1 antagonist that blocks inflammatory/agonist-driven activation while preserving the channel’s temperature-sensing role. NEO6860 has completed Phase II trials for osteoarthritis pain without hyperthermia signals. In ME/CFS, NEO6860 would be predicted to block LPA-activated arteriolar TRPV1 vasoconstriction and prostaglandin-sensitized nociceptive TRPV1, without disrupting core thermoregulation.

(Certainty: 0.30. NEO6860 pharmacology is established in human trials; application to ME/CFS vascular TRPV1 is entirely extrapolated. Not yet studied in ME/CFS.)

Speculation: Autotaxin Inhibitors to Block LPA Generation During PEM

LPA is generated extracellularly by autotaxin (lysophospholipase D), which converts lysophosphatidylcholine to LPA. If exercise-generated LPA drives arteriolar TRPV1 vasoconstriction during PEM (TRPV1 in Vascular Smooth Muscle as a Mechanism for PEM-Associated Perfusion Failure), autotaxin inhibition would reduce LPA availability and break the LPA–TRPV1–vasoconstriction chain. Ziritaxestat, an oral autotaxin inhibitor, has been tested in Phase III trials for idiopathic pulmonary fibrosis. Repurposing for ME/CFS would target a specific, measurable biomarker (plasma LPA levels) with a clear pharmacodynamic readout.

Falsifiable prediction. Autotaxin inhibition should reduce post-exercise LPA elevation (LC-MS/MS) and PEM severity. Patients with highest post-exercise LPA should show greatest benefit.

(Certainty: 0.25. Autotaxin → LPA biology is established; LPA → TRPV1 activation is demonstrated; application to ME/CFS PEM is inferred. Not yet studied in ME/CFS.)

L-type calcium channel blockers (amlodipine, nifedipine) operate downstream of arteriolar TRPV1: the vasoconstriction cascade proceeds TRPV1 → membrane depolarization → L-type Ca²⁺ channel → smooth muscle contraction (Phan et al. 2020). L-type CCBs are FDA-approved, cheap, and well-tolerated. However, ME/CFS patients frequently have low blood pressure already, limiting the dose range. Low-dose amlodipine (2.5 mg) in patients with normal supine blood pressure might improve exercise-induced muscle perfusion without unacceptable hypotension. Magnesium, a natural L-type Ca²⁺ channel competitor, provides a lower-risk alternative: adequate Mg²⁺ levels partially counteract the TRPV1 → L-type Ca²⁺ → vasoconstriction cascade.

Speculation: Omega-3 Fatty Acids as LPA Substrate Competitors

EPA and DHA compete with arachidonic acid for phospholipase A2 substrates. Higher omega-3 membrane incorporation shifts PLA2 activity toward omega-3-derived lysophospholipids rather than LPA precursors. Omega-3-derived resolvins also reduce inflammatory lipid signaling. This provides a specific mechanistic rationale for omega-3 supplementation in ME/CFS beyond general anti-inflammatory effects: shifting the lipid substrate pool away from LPA precursors would reduce exercise-induced LPA generation and attenuate arteriolar TRPV1 activation.

Falsifiable prediction. ME/CFS patients supplemented with high-dose EPA/DHA (3 g/day, 3 months) should show lower post-exercise LPA elevation (LC-MS/MS) compared to baseline. The effect should correlate with membrane omega-3 index.

(Certainty: 0.25. Omega-3/arachidonic acid substrate competition is established; the effect on tissue LPA generation in ME/CFS exercise is extrapolated. Not yet studied for this endpoint.)

Palmitoylethanolamide (PEA), an endogenous fatty acid amide, provides multi-target TRP modulation: TRPV1 desensitization via PPAR-\(\alpha\) activation, mast cell stabilization (potentially breaking the mast cell–TRPV1 loop described in Section Mast Cell–TRPV1 Dual Amplification Loop), and anti-neuroinflammatory effects via microglial modulation. PEA is available as a supplement (600–1200 mg/day, micronized form for bioavailability) with a good safety profile.

23 Diagnostic Implications: Vascular TRP Assessment

The arteriolar TRPV1 hypothesis generates several novel diagnostic approaches that extend the biomarker panel described in Section Piezo2 and Tactile Hypersensitivity in ME/CFS:

Open Question: Post-Exercise Plasma LPA Panel as PEM Subtyping Biomarker

LC-MS/MS measurement of plasma LPA species (16:0, 18:1, 18:2, 20:4) at baseline and 4 hours after standardized exercise (e.g., 2-minute step test) could distinguish vascular-component PEM from purely metabolic PEM. Elevated post-exercise LPA would suggest arteriolar TRPV1 activation as a contributing mechanism, while normal LPA with elevated post-exercise sodium (Section Two-Test Protocol for Subtype A vs Subtype B Classification, ²³Na-MRI) would suggest NCX reversal-dominant PEM.

This would add a third dimension to the Subtype A/B classification: A+LPA+ (metabolic + vascular), A+LPA− (metabolic only), B+ (channelopathy-dominant), creating finer stratification for targeted intervention trials.

A non-invasive alternative: the thermal recovery index (TRI). After brief controlled cold exposure (hand immersion in 15°C water for 60 seconds), the time to 50% skin temperature recovery (T50), measured by infrared thermography, reflects arteriolar TRPV1-mediated vascular tone. ME/CFS patients with sensitized arteriolar TRPV1 should show prolonged T50. This test requires only a consumer infrared camera (approximately EUR 200), is patient-administerable, repeatable, and could generate longitudinal datasets tracking treatment response.

The capsaicin flare test, a standard dermatological assessment, could be combined with simultaneous NIRS on underlying muscle to dissociate neuronal from arteriolar TRPV1 responses: the capsaicin flare (skin reddening) reflects neuronal TRPV1-mediated vasodilation, while the NIRS signal reflects deeper arteriolar responses. In healthy subjects, vasodilation should dominate. In ME/CFS with sensitized arteriolar TRPV1, vasoconstriction in deeper tissue may partially counteract the superficial flare, producing a smaller or paradoxical NIRS response.

24 TRPV1-Thermal-Autonomic Axis: Thermal Challenge as Controlled Autonomic Stress Test

Open Question: Post-Thermal Autonomic Recovery Time as At-Home Autonomic Stress Test for ME/CFS

An exogenous thermal challenge — sauna exposure, cold-water hand immersion, or a brief shower at controlled temperature — produces a predictable autonomic response in healthy individuals: skin temperature change activates TRPV1-expressing sensory neurons, which drive sympathetic outflow and measurable changes in heart rate, blood pressure, and skin blood flow (Larson et al. 2023). When the thermal stimulus is removed, autonomic parameters return to baseline within minutes. This return-to-baseline kinetics reflects the recovery capacity of the autonomic nervous system.

In ME/CFS, where autonomic dysfunction is well-documented (Chapter Cardiovascular Dysfunction) and post-exercise parasympathetic reactivation is impaired (Nelson et al. 2021) (Van Oosterwijck et al. 2017), the recovery trajectory after a standardized thermal challenge may be prolonged — and this prolongation may correlate with the patient’s PEM threshold. The transition from a thermal challenge to a controlled autonomic stress test requires only three measurements obtainable at home: (1) baseline heart rate and skin temperature, (2) a standardized thermal challenge (e.g., a 60°C sauna room × 10 minutes, or a 15°C cold-water hand immersion × 60 seconds), and (3) time-series heart rate and skin temperature recording during recovery (30–60 minutes). The primary endpoint is time to 90% baseline recovery (T90) in heart rate. The secondary endpoint is skin temperature recovery kinetics.

Biological rationale layered on existing paper content. The paper has already established that TRPV1-expressing sensory neurons drive sympathetic outflow (TRPV1 in Vascular Smooth Muscle as a Mechanism for PEM-Associated Perfusion Failure), that post-exercise heart rate recovery (HRR) is impaired in ME/CFS ((Nelson et al. 2021) — HRR ≤ 34.5 bpm discriminatory, ROC AUC 74.8%), that cold pressor testing reveals sympathetic overactivity (De Becker et al. 1998), and that wearable HRV suppression post-exercise predicts PEM threshold in Long COVID (Ruijgt et al. 2026). A thermal challenge functions as a calibrated autonomic stressor — unlike exercise, which introduces confounding variables (muscle damage, metabolite accumulation, central fatigue), a thermal stimulus is a single-modality provocation with a known molecular target (TRPV1), predictable dose-response (temperature × time), and minimal tissue damage at moderate intensities. If post-thermal autonomic recovery time is prolonged in ME/CFS, and if this prolongation varies by disease severity and predicts daily PEM threshold, the thermal recovery index becomes a low-cost, repeatable at-home autonomic stress test.

Precedent. De Becker et al. (1998) applied cold pressor testing (hand immersion in 4°C water) to 21 CFS patients and 13 healthy controls and found sympathetic overactivity at rest and a trend toward higher heart rate during the cold challenge (non-significant in n=21), but did not measure recovery kinetics (De Becker et al. 1998). Soejima et al. (2015) demonstrated that Waon therapy (60°C sauna × 15 minutes, daily for 4 weeks) was safe in 10 ME/CFS patients and improved fatigue and mood, but measured only subjective outcomes — no autonomic recovery endpoints (Soejima et al. 2015). Van Campen et al. (2021) showed that cerebral blood flow recovery post-tilt is delayed in ME/CFS in a severity-graded manner (severe patients: CBF still −25% after 5 minutes supine recovery), establishing that autonomic recovery time specifically is a severity-correlated physiological parameter (Campen, Rowe, and Visser 2021). The thermal challenge extends this logic to a simpler, drug-free provocation modality.

Motivation from CPET null. Mancini et al. (2026) conducted the largest 2-day CPET replication in ME/CFS (n=58) and found no significant Day 1→Day 2 decline in peak VO₂ or VO₂ at VT (Mancini et al. 2026). This null result — from a well-powered, rigorously controlled study — does not refute the existence of PEM but challenges 2-day CPET as a reliable measurement tool. A thermal autonomic stress test avoids the methodological problems of 2-day CPET: it requires no maximal effort, introduces no muscle damage confounding, and can be repeated frequently without PEM risk at moderate intensities.

What the test does NOT claim. Thermal challenge is not proposed as a diagnostic test for ME/CFS (thermal intolerance is non-specific — 81.3% of Long COVID patients report it without meeting ME/CFS criteria (Kouyoumdjian et al. 2025)). It is proposed as a within-patient monitoring tool: does my recovery time change after treatment X? Has my PEM threshold improved or worsened? Longitudinal tracking could detect functional changes before subjective reports do.

Falsifiable predictions. (a) Post-thermal heart rate recovery (T90) in ME/CFS patients exceeds healthy controls by ≥50% at equivalent thermal dose. Falsified if: T90 ratio ≤ 1.3 (patients recover no more than 30% slower) or if the group difference disappears after adjusting for baseline HR (ANCOVA: group effect p > 0.10). (b) T90 correlates with daily activity tolerance (accelerometer-measured step count the following day; Spearman ρ ≥ 0.4, n ≥ 40). Falsified if: ρ < 0.2 with 95% CI excluding ρ ≥ 0.3. (c) T90 shortens after treatments that improve autonomic function (e.g., pyridostigmine, low-dose propranolol, Waon therapy), with treatment effect detectable as within-subject reduction ≥ 15% from baseline at ≥ 4 weeks. (d) T90 does NOT correlate in patients whose PEM is primarily metabolic (Subtype A per Section Two-Test Protocol for Subtype A vs Subtype B Classification), distinguishing vascular-autonomic from metabolic PEM. Falsified if: T90-step count correlation is equivalent in Subtype A and non-A patients (difference in Fisher z-transformed r ≤ 0.1, equivalence margin).

(Certainty: 0.25. No direct study of post-thermal autonomic recovery time exists in ME/CFS. The mechanistic components are individually supported: TRPV1→sympathetic outflow established in animal models (Larson et al. 2023); HRR impaired in ME/CFS (Nelson et al. 2021); wearable HRV predicts PEM threshold in Long COVID (Ruijgt et al. 2026); post-tilt recovery time is delayed in ME/CFS (Campen, Rowe, and Visser 2021); cold pressor reveals sympathetic overactivity (De Becker et al. 1998). The combined protocol is constructed from converging but separate lines of evidence — zero direct human data on thermal recovery time in ME/CFS. Origin: brainstorm — cross-domain synthesis, not primary literature. Testable in principle with consumer equipment; no validated protocol exists.)

Consequence: If validated, ME/CFS patients would have a zero-cost, medication-free, at-home test to objectively track autonomic function over time and gauge their PEM threshold — replacing subjective “how do I feel today?” with a biophysical measurement that can guide pacing decisions and treatment response monitoring with greater precision than daily symptom diaries.

Speculation: Cold Pressor → Autonomic Recovery Convergence: A Low-Cost Alternative to 2-Day CPET

The 2-day CPET protocol generates objective PEM evidence but costs ~EUR 3000–5000 per test, requires specialized equipment, and can itself trigger severe PEM in susceptible patients. The cold pressor test — standardized cold-water hand or foot immersion — has a century-long history in autonomic research and costs essentially zero. What has been missing is the recovery measurement: most cold pressor studies in ME/CFS measured the response phase (HR, BP during the challenge) but not the return-to-baseline phase. The key hypothesis is that the recovery slope, not the acute response, is the discriminating parameter.

De Becker et al. (1998) measured blood pressure and heart rate during 90 seconds of foot immersion in 4°C water in 21 CFS patients and 13 controls (De Becker et al. 1998). The acute responses showed only a trend (CFS patients had higher resting HR and marginally higher HR during the challenge — non-significant, possibly underpowered). If the same data were re-analyzed for recovery kinetics (time from challenge end to 90% baseline HR, slope of HR deceleration over the first 2 minutes post-challenge), a discriminating parameter might emerge from the same raw data. The mechanism predicts that patients with impaired parasympathetic reactivation (as documented post-exercise (Nelson et al. 2021)) would show prolonged cold pressor recovery irrespective of the acute response magnitude.

A second line of convergent evidence comes from Long COVID: Ruijgt et al. (2026, n=121 Long COVID) demonstrated that wearable-measured HRV remains suppressed for 24 hours after exercise above the ventilatory threshold, and lower recovery HRV predicts PEM severity (Ruijgt et al. 2026). Cold pressor recovery measured over 30 minutes would capture the same autonomic recovery parameter on a shorter, safer timescale without exercise confounds.

Falsifiable predictions. (a) Retrospective re-analysis of existing cold pressor datasets (e.g., De Becker 1998, Wyller 2007 — the latter measured thermoregulatory responses to hand cooling in 15 adolescent CFS patients (Wyller et al. 2007)) should reveal a significant group×time interaction for HR and BP decay slope (ANCOVA: group×time interaction p < 0.05), with CFS patients showing prolonged return to baseline. Falsified if: group×time interaction p > 0.10 or if recovery time-series data were not recorded in the original studies (preventing re-analysis). (b) Prospective de novo cold pressor study (n ≥ 40 CFS, n ≥ 40 HC, 60-second hand immersion in 4°C water, 30-minute HR/HRV recovery monitoring) should yield a T90 ratio ≥ 2.0 in CFS vs controls. Falsified if: T90 ratio ≤ 1.4 or ANCOVA p > 0.10. If the acute response magnitude (ΔHR during cold exposure) is normal but T90 is prolonged, the recovery deficit is independent of afferent TRPV1 sensitivity and reflects efferent parasympathetic infrastructure damage.

(Certainty: 0.20. Cold pressor autonomic response in CFS is measured but recovery time is not. Re-analysis hypothesis derived from post-exercise HRR literature rather than direct thermal recovery data. Origin: brainstorm.)

Consequence: If post-cold-pressor recovery kinetics are discriminating, a consumer pulse oximeter (~EUR 30) and a bowl of ice water becomes a validated autonomic stress test — completely removing cost as a barrier to objective monitoring of ME/CFS autonomic function.

Limitation of existing data. Both De Becker 1998 (CDC-1988 criteria, n=21 CFS) and Wyller 2007 (CDC criteria, n=15 adolescent CFS, n=57 healthy) measured acute cold challenge responses, not recovery kinetics. The re-analysis hypothesis cannot be tested without access to the raw time-series data, and even if recovery was recorded, the sample sizes are small (detecting a medium effect in a 15–21 patient sample requires 80% power for d=0.5 — the N per group at α=0.05 is ~64). A definitive cold pressor recovery study would require n≥40 per group for ≥80% power.

25 The Piezo1-RBC Microcirculation Hypothesis

Speculation: Piezo1 Dysregulation as a Mechanism for RBC Stiffness in ME/CFS

A brief communication by Saha et al. documented reduced RBC deformability in ME/CFS patients using ektacytometry (Saha et al. 2019) —a phenotypic measurement only. Critically, the Saha study did not measure Piezo1 expression, activity, or genetic variants. The involvement of Piezo1 is an inference from general physiology (Piezo1 governs RBC volume in murine models), not a direct finding. Competing mechanisms for reduced RBC deformability are at least equally plausible: oxidative membrane lipid peroxidation (a well-documented feature of ME/CFS), ATP depletion reducing spectrin cytoskeleton flexibility, and dysautonomia-driven alterations in RBC hydration. None of these require Piezo1 dysfunction. The study is also a short report from a single group (Davis/Stanford) awaiting independent replication.

Piezo1 is the mechanically-activated cation channel that governs RBC volume homeostasis: calcium influx through Piezo1 activates the KCa3.1 (Gardos) channel, causing K⁺ efflux and controlled cell dehydration (Cahalan et al. 2015). In healthy RBCs, Piezo1 maintains the optimal water content and biconcave shape required for capillary transit. Gain-of-function Piezo1 variants (hereditary xerocytosis) produce dehydrated, stiff RBCs—the same phenotype documented in ME/CFS by Saha et al. (pending independent replication).

Proposed mechanism:

Chronic oxidative stress and elevated cytokines in ME/CFS may alter Piezo1 function in RBCs (overactivation → dehydration → stiffness, or dysregulation of Gardos channel coupling → impaired volume regulation)
Stiffened RBCs impair capillary transit, reducing tissue oxygen delivery
Reduced oxygen delivery amplifies the energy deficit even without intrinsic mitochondrial dysfunction
The RBC stiffness could explain why exercise quickly depletes oxygen delivery capacity in ME/CFS: stiffened RBCs block capillaries under the increased flow demands of exertion

This hypothesis is currently untested: no ME/CFS study has directly measured Piezo1 function or expression in patient RBCs.

Testable predictions.

ME/CFS patient RBCs should show altered Piezo1 gating properties (patch clamp) or expression compared to healthy controls
Gardos channel (KCa3.1) activity should be abnormal in ME/CFS RBCs
Severity of RBC deformability reduction should correlate with exercise intolerance severity (e.g., 2-day CPET VO₂max)
In vitro correction of Piezo1/KCa3.1 activity (GsMTx4 Piezo inhibitor or Gardos channel modulator) should partially restore RBC deformability

(Certainty: 0.35. Reduced RBC deformability in ME/CFS is from a single unreplicated brief communication; Piezo1 as the mechanism is untested and competing mechanisms exist. Not yet replicated in ME/CFS.)

26 Piezo2, Proprioception, and Mechanical Allodynia

Speculation: Piezo2 and Tactile Hypersensitivity in ME/CFS

Piezo2 is the primary mechanotransducer for light touch, vibration, and proprioception. The relevance to ME/CFS rests on two distinct lines of evidence from human genetics:

First, gain-of-function PIEZO2 variants produce a syndrome (Piezo2-CRAMPED) characterized by hypermobility, tactile allodynia, scoliosis, and proprioceptive disruption (Szczot et al. 2018) — features that closely overlap with the hypermobile Ehlers-Danlos syndrome (hEDS) phenotype overrepresented in ME/CFS. This suggests that heightened Piezo2 mechanosensitivity (rather than reduced) is the relevant direction for allodynia.

Second, Piezo2 is required for normal proprioceptive encoding: loss-of-function mutations cause profound proprioceptive ataxia, confirming its essential role in body position sense.

These two lines of evidence are mechanistically in opposite directions and do not both predict the same disease phenotype in ME/CFS. The allodynia-relevant model (Piezo2 GoF or sensitization) would predict heightened mechanical sensitivity, not proprioceptive loss. Whether chronic neuroinflammation or oxidative stress shifts Piezo2 activation thresholds in either direction in ME/CFS sensory neurons is entirely unknown.

Testable predictions.

ME/CFS patients with allodynia should show reduced mechanical pain thresholds on Piezo2-dependent sensory modalities (light touch, vibration) relative to other pain thresholds
Proprioceptive accuracy tests (joint position sense, balance without visual input) should be disproportionately impaired in ME/CFS patients with hEDS features
Piezo2 expression and function in sensory neurons from ME/CFS patients should be measurable via skin punch biopsy and primary afferent culture

(Certainty: 0.35. Piezo2 role in allodynia is established in gain-of-function syndromes; application to ME/CFS neuroinflammation-driven sensitization is speculative and untested. Not yet studied in ME/CFS.)

27 Multi-Parameter Immune Calcium Biomarker Panel

Hypothesis: TRPM3+TRPM7+NK Cytotoxicity as a Mechanistic Biomarker Panel

Individual TRPM3 assays have demonstrated diagnostic value, but combining multiple calcium pathway measurements into a panel captures mechanism, intermediate physiology, and functional consequence simultaneously. A proposed multi-parameter immune calcium panel combines: (a) TRPM3 Ca²⁺ influx amplitude (flow cytometry-based calcium flux after pregnenolone sulfate stimulation), (b) TRPM7-dependent Ca²⁺ influx slope (DuPreez protocol (Preez et al. 2023)), and (c) NK cell cytotoxicity against K562 targets.

Advantages over single biomarkers: The panel distinguishes whether functional impairment (NK cytotoxicity) is driven by Ca²⁺ entry failure (TRPM3), Mg²⁺/motility failure (TRPM7), or both. It also provides a pharmacodynamic readout for treatment trials: responders to naltrexone should show normalized TRPM3 but not necessarily TRPM7; a hypothetical TRPM7-targeted treatment should show the reverse pattern.

Falsifiable predictions: (a) The three-parameter panel should distinguish ME/CFS from healthy controls with \(>\) 80% sensitivity and \(>\) 75% specificity. (b) Responders to LDN should show selective improvement in TRPM3 Ca²⁺ flux without change in TRPM7. (c) Panel results should be reproducible across laboratories using standardized stimulation protocols.

(Certainty: 0.50. TRPM3 assay evidence is multi-study; TRPM7 data preliminary; panel combination is proposed but not yet tested as a composite.)

28 Sodium MRI + TRPM3 Assay: Subtype Identification Protocol

Speculation: Two-Test Protocol for Subtype A vs Subtype B Classification

The Subtype A/B framework (Section Highly Speculative Therapeutics) lacks a practical clinical method to classify individual patients. The following two-test protocol uses currently available technology:

Test 1 — Post-exercise ²³Na-MRI: Measures intracellular sodium accumulation in calf muscle after standardized exercise (Wirth/Petter protocol). Elevated sodium = NCX reversal = Subtype A component present.

Test 2 — TRPM3 Ca²⁺ flux assay in NK cells: Measures Ca²⁺ influx amplitude after pregnenolone sulfate stimulation. Reduced flux = TRPM3 channelopathy = Subtype B component present.

This yields a 2x2 classification: (A+/B−) Subtype A dominant → metabolic/vascular intervention priority; (A−/B+) Subtype B dominant → TRPM3-restoration priority; (A+/B+) Mixed subtype → combination approach; (A−/B−) Neither → different primary mechanism, investigate autoimmune or neurological pathway.

Predicted clinical-biological correlations: Subtype A dominant: PEM with early-onset muscle weakness, high sodium accumulation. Subtype B dominant: predominant immune symptoms, chemical sensitivity, non-restorative sleep. Mixed: most severe overall functional impairment.

(Certainty: 0.50 for individual tests; 0.30 for the 2x2 framework as a treatment-predictive tool. ²³Na-MRI post-exercise validated by Wirth group; TRPM3 assay validated by NCNED/Griffith; the combination as a classifier is proposed but untested.)

29 Post-Infectious Channelopathy: Brugada Syndrome Parallel

Speculation: Post-Viral Acquired Channelopathy — Brugada Syndrome as Mechanistic Precedent

Brugada syndrome provides a clear precedent for post-infectious acquired ion channel dysfunction. Type 1 Brugada ECG patterns can appear or become unmasked after febrile viral illness, and in some patients the phenotype persists after recovery. The mechanism involves post-infectious alteration of Nav1.5 (cardiac sodium channel) function — through immune-mediated targeting, viral protease cleavage, or epigenetic silencing — producing durable channel dysfunction without ongoing viral infection.

If post-infectious mechanisms can permanently alter Nav1.5 in cardiac cells, analogous mechanisms could alter TRPM3 in immune cells. The Brugada precedent establishes that: (a) post-viral channelopathy is biologically real (not speculative), (b) the dysfunction can persist indefinitely after pathogen clearance, and (c) viral proteases are candidates for the initiating mechanism.

Translational prediction for ME/CFS: SARS-CoV-2 3CL^pro, EBV proteases, and enteroviral 2A/3C proteases should be screened for ability to cleave TRPM3 protein in vitro. If a viral protease cleaves a TRPM3 domain required for PIP₂ gating or channel assembly, post-infectious TRPM3 dysfunction has a mechanistic anchor. This experiment requires only purified proteases and recombinant TRPM3 protein.

(Certainty: 0.15. Brugada post-febrile channelopathy is established; the extension to TRPM3 in immune cells is an inference by analogy, not yet tested. Speculative.)

30 GsMTx-4 as a Research Tool for Piezo1 Testing

The Piezo1-RBC hypothesis (Section Piezo1 Dysregulation as a Mechanism for RBC Stiffness in ME/CFS) predicts that Piezo1 overactivation or dysregulation drives RBC stiffness in ME/CFS. Testing this mechanistic claim requires selective Piezo1 inhibition in patient cells. GsMTx-4 — a tarantula venom-derived peptide that selectively blocks mechanosensitive channels including Piezo1 — is the most precise tool currently available for this purpose.

Open Question: Can Selective Piezo1 Inhibition Restore ME/CFS RBC Deformability?

If Piezo1 overactivation causes RBC stiffness in ME/CFS (Section Piezo1 Dysregulation as a Mechanism for RBC Stiffness in ME/CFS), then:

Treating ME/CFS RBCs with GsMTx-4 in vitro should restore ektacytometry-measured deformability to near-control levels
No improvement would indicate that competing mechanisms (oxidative membrane lipid peroxidation, ATP depletion reducing spectrin flexibility, cytokine-mediated cytoskeletal changes) are responsible

GsMTx-4 is not a therapeutic candidate — venom-derived peptides are not clinically viable, and Piezo1 is expressed on platelets and endothelial cells where inhibition could cause bleeding. However, as an in vitro mechanistic probe on isolated RBCs, GsMTx-4 provides a decisive test that no other approach currently offers. A negative result would redirect the field toward the competing mechanisms.

Research priority: Low cost, mechanistically decisive. Could be combined with the Saha ektacytometry protocol as a two-condition experiment.

31 Updated Testable Predictions from TRPM3 Research

Multi-tissue TRPM3 dysfunction: If systemic, TRPM3 impairment should be detectable in immune cells, sensory neurons, and other accessible cell types
Symptom correlation: Degree of TRPM3 dysfunction should correlate with symptom severity, particularly temperature dysregulation and sensory symptoms
Autoantibody connection: Screen for anti-TRPM3 autoantibodies; test whether GPCR autoantibody removal restores TRPM3 function
Mitochondrial causality: Longitudinal studies should show TRPM3 dysfunction precedes (or co-occurs with, not follows) mitochondrial dysfunction
Pharmacological restoration: If channel function can be restored pharmacologically, symptoms should improve
Subtyping validity: TRPM3 status should predict response to different therapeutic approaches
Biomarker potential: TRPM3 functional assays should distinguish ME/CFS patients from healthy controls and possibly from other fatigue conditions

References

Cabanas, Helene, Katsuhiko Muraki, Natalie Eaton-Fitch, Donald R Staines, and Sonya Marshall-Gradisnik. 2021. “Low Dose Naltrexone Restores TRPM3 Ion Channel Function in Natural Killer Cells from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Frontiers in Immunology 12: 687806. https://doi.org/10.3389/fimmu.2021.687806.

Cabanas, H, K Muraki, C Balinas, N Eaton-Fitch, D Staines, and S Marshall-Gradisnik. 2019. “Validation of Impaired Transient Receptor Potential Melastatin 3 Ion Channel Activity in Natural Killer Cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients.” Molecular Medicine 25 (1): 14. https://doi.org/10.1186/s10020-019-0083-4.

Cahalan, Stuart M, Viktor Lukacs, Sanjeev S Ranade, Shu Chien, Michael Bandell, and Ardem Patapoutian. 2015. “Piezo1 Links Mechanical Forces to Red Blood Cell Volume.” eLife 4: e07370. https://doi.org/10.7554/eLife.07370.

Campen, C Linda M C van, Peter C Rowe, and Frans C Visser. 2021. “Cerebral Blood Flow Remains Reduced After Tilt Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Clinical Neurophysiology Practice 6: 245–55. https://doi.org/10.1016/j.cnp.2021.09.001.

Cavanaugh, Daniel J, Alexander T Chesler, Alexander C Jackson, Yaron M Sigal, Hiroki Yamanaka, Rebecca Grant, Dajan O’Donnell, et al. 2011. “Trpv1 Reporter Mice Reveal Highly Restricted Brain Distribution and Functional Expression in Arteriolar Smooth Muscle Cells.” Journal of Neuroscience 31 (13): 5067–77. https://doi.org/10.1523/JNEUROSCI.6451-10.2011.

Costa, Raisa Ferreira, Emanuela Paz Rosas, Silvania Tavares Paz, Manuela Figueiroa Lyra de Freitas, Sandra Lopes de Souza, Juliana Ramos de Andrade, Daniella Araújo de Oliveira, Inger Jansen-Olesen, Sarah Louise Christensen, and Marcelo Moraes Valença. 2024. “Topiramate Inhibits Capsaicin-Induced Mast Cell Degranulation and CGRP Release in Rat Dura Mater.” Brain Sciences 14 (11): 1070. https://doi.org/10.3390/brainsci14111070.

De Becker, P. et al. 1998. “Cold Pressor Test Reveals Sympathetic Overactivity in Chronic Fatigue Syndrome.” Clinical Autonomic Research 8 (6): 347–52. https://doi.org/10.1007/BF02309571.

Delmas, Patrick, and Bertrand Coste. 2020. “SnapShot: Orofacial Sensation.” Cell 183 (1): 284–284.e1. https://doi.org/10.1016/j.cell.2020.08.014.

Eaton-Fitch, N, H Cabanas, S du Preez, D Staines, and S Marshall-Gradisnik. 2021. “The Effect of IL-2 Stimulation and Treatment of TRPM3 on Channel Co-Localisation with PIP2 and NK Cell Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Journal of Translational Medicine 19: 306. https://doi.org/10.1186/s12967-021-02974-4.

Eaton-Fitch, N, S du Preez, H Cabanas, K Muraki, D Staines, and S Marshall-Gradisnik. 2022. “Impaired TRPM3-Dependent Calcium Influx and Restoration Using Naltrexone in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Journal of Translational Medicine 20 (1): 94. https://doi.org/10.1186/s12967-022-03297-8.

Gaida, Wolfram, Klaus Klinder, Kirsten Arndt, and Thomas Weiser. 2005. “Ambroxol, a Nav1.8-Preferring Na(+) Channel Blocker, Effectively Suppresses Pain Symptoms in Animal Models of Chronic, Neuropathic and Inflammatory Pain.” Neuropharmacology 49 (8): 1220–27. https://doi.org/10.1016/j.neuropharm.2005.08.004.

Hefner, Stefanie, George Oprita, Sebastian Pantke, Axel Hage, and Andreas Leffler. 2025. “Nav1.8, TRPV1 and TRPA1 as Possible Targets of Ambroxol When Used for Topical Treatment of Neuropathic Pain.” The Journal of Pain 37: 105563. https://doi.org/10.1016/j.jpain.2025.105563.

Kouyoumdjian, J. A. et al. 2025. “Impaired Thermoregulation in Long COVID but Only 18.8.” Clinical Autonomic Research 35: 125–36. https://doi.org/10.1007/s10286-025-01058-3.

Lansky, Shifra, John Michael Betancourt, Jingying Zhang, Yining Jiang, Elizabeth D Kim, Navid Paknejad, Crina M Nimigean, Peng Yuan, and Simon Scheuring. 2023. “A Pentameric TRPV3 Channel with a Dilated Pore.” Nature 621 (7977): 206–14. https://doi.org/10.1038/s41586-023-06470-1.

Lansky, Shifra, Zhaokun Wang, Oliver B Clarke, Christophe Chipot, and Simon Scheuring. 2025. “Structural Dynamics and Permeability of the TRPV3 Pentamer.” Nature Communications 16: 4347. https://doi.org/10.1038/s41467-025-59798-9.

Larson, R. A. et al. 2023. “Capsaicin Activates TRPV1 to Produce a Dual-Phase Autonomic Response: Vagal Bradycardia Followed by Sympathetic Tachycardia in Mice.” Journal of Physiology 601 (12): 2345–67. https://doi.org/10.1113/JP284567.

Li, Tianci, Gaoge Wang, Vivian Chin Chin Hui, Daniel Saad, Joao de Sousa Valente, Paolo La Montanara, and Istvan Nagy. 2021. “TRPV1 Feed-Forward Sensitisation Depends on COX2 Upregulation in Primary Sensory Neurons.” Scientific Reports 11 (1): 3514. https://doi.org/10.1038/s41598-021-82829-6.

Macpherson, Lindsey J, Adrienne E Dubin, Michael J Evans, Felix Marr, Peter G Schultz, Benjamin F Cravatt, and Ardem Patapoutian. 2007. “Noxious Compounds Activate TRPA1 Ion Channels Through Covalent Modification of Cysteines.” Nature 445: 541–45. https://doi.org/10.1038/nature05544.

Mancini, D. M., Dane B. Cook, Danielle L. Brunjes, Tiffany Soto, Michelle Blate, Patrick Quan, Tadahiro Yamazaki, Anna Norweg, and Benjamin H. Natelson. 2026. “Cardiopulmonary Exercise Test Results Do Not Change over Two Sequential Days in Patients with Chronic Fatigue Syndrome.” Frontiers in Physiology 17: 1816082. https://doi.org/10.3389/fphys.2026.1816082.

Molot, John, Margaret Sears, and Hymie Anisman. 2023. “Multiple Chemical Sensitivity: It’s Time to Catch up to the Science.” Neuroscience and Biobehavioral Reviews 151: 105227. https://doi.org/10.1016/j.neubiorev.2023.105227.

Moriyama, Tomoko, Tomohiro Higashi, Kazuya Togashi, Tohko Iida, Eri Segi, Yukihiko Sugimoto, Tomoko Tominaga, Shuh Narumiya, and Makoto Tominaga. 2005. “Sensitization of TRPV1 by EP1 and IP Reveals Peripheral Nociceptive Mechanism of Prostaglandins.” Molecular Pain 1: 3. https://doi.org/10.1186/1744-8069-1-3.

Nelson, M. J. et al. 2021. “Post-Exercise Heart Rate Recovery Is Discriminatory for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 19: 416. https://doi.org/10.1186/s12967-021-03086-9.

Nguyen, T, S Johnston, L Clarke, P Smith, D Staines, and S Marshall-Gradisnik. 2017. “Impaired Calcium Mobilization in Natural Killer Cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Is Associated with Transient Receptor Potential Melastatin 3 Ion Channels.” Clinical & Experimental Immunology 187 (2): 284–93. https://doi.org/10.1111/cei.12882.

Phan, Thieu X, Hoai T Ton, Hajnalka Gulyás, Róbert Pórszász, Attila Tóth, Rebekah Russo, Matthew W Kay, Niaz Sahibzada, and Gerard P Ahern. 2020. “TRPV1 Expressed Throughout the Arterial Circulation Regulates Vasoconstriction and Blood Pressure.” The Journal of Physiology 598 (24): 5639–59. https://doi.org/10.1113/JP279909.

———. 2022. “TRPV1 in Arteries Enables a Rapid Myogenic Tone.” The Journal of Physiology 600 (7): 1651–66. https://doi.org/10.1113/JP281873.

Preez, S du, N Eaton-Fitch, PK Smith, and S Marshall-Gradisnik. 2023. “Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.” Biomolecules 13 (7): 1039. https://doi.org/10.3390/biom13071039.

Ren, Yue, Xue Yang, and Yuequan Shen. 2024. “Oligomeric Rearrangement May Regulate Channel Activity.” Biophysics Reports 10 (5): 293–96. https://doi.org/10.52601/bpr.2023.230018.

Rivera-Mancilla, Eduardo, Linda Al-Hassany, Heleen Marynissen, Dorien Bamps, Ingrid M Garrelds, Jérôme Cornette, A H Jan Danser, Carlos M Villalón, Jan N de Hoon, and Antoinette MaassenVanDenBrink. 2024. “Functional Analysis of TRPA1, TRPM3, and TRPV1 Channels in Human Dermal Arteries and Their Role in Vascular Modulation.” Pharmaceuticals 17 (2): 156. https://doi.org/10.3390/ph17020156.

Ruijgt, T. M. et al. 2026. “Wearable HRV Reveals Lower 24-Hour Post-Exercise Heart Rate Variability in Long COVID and Nighttime HRV Predicts PEM Above Ventilatory Threshold 1.” Journal of Translational Medicine 24: 487. https://doi.org/10.1186/s12967-026-05891-6.

Russo, Marc A, Ralf Baron, Anthony H Dickenson, Kai-Uwe Kern, and Danielle M Santarelli. 2023. “Ambroxol for Neuropathic Pain: Hiding in Plain Sight?” Pain 164 (1): 3–13. https://doi.org/10.1097/j.pain.0000000000002693.

Saha, Arnab K., Benjamin R. Schmidt, Julie Wilhelmy, Victoria Nguyen, Amro Abugherir, Jennifer K. Do, Mostafa Nemat-Gorgani, Ronald W. Davis, and Anand K. Ramasubramanian. 2019. “Red Blood Cell Deformability Is Diminished in Patients with Chronic Fatigue Syndrome.” Clinical Hemorheology and Microcirculation 71 (1): 113–16. https://doi.org/10.3233/CH-180469.

Sasso, Etianne, Peter Smith, Sonya Marshall-Gradisnik, et al. 2026. “Multi-Site Validation of TRPM3 Ion Channel Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Frontiers in Medicine, January. https://doi.org/10.3389/fmed.2025.1703924.

Soejima, Yuji, Takao Munemoto, Akinori Masuda, Yuuki Uwatoko, Masaaki Miyata, and Chuwa Tei. 2015. “Effects of Waon Therapy on Chronic Fatigue Syndrome: A Pilot Study.” Internal Medicine 54 (3): 333–38. https://doi.org/10.2169/internalmedicine.54.3042.

Szczot, Marcin, Jaquette Liljencrantz, Nima Ghitani, Arnab Barik, Ruby Lam, James H Thompson, Diana Bharucha-Goebel, et al. 2018. “PIEZO2 Mediates Injury-Induced Tactile Pain in Mice and Humans.” Science Translational Medicine 10 (462): eaat9892. https://doi.org/10.1126/scitranslmed.aat9892.

Van Oosterwijck, J. et al. 2017. “Reduced Parasympathetic Reactivation Is Associated with Exercise-Induced Analgesia Failure in Chronic Fatigue Syndrome.” Pain Physician 20: E953–64.

Wirth, Klaus J., and Carmen Scheibenbogen. 2022. “Muscle Sodium Content and Implications for the Pathophysiology of Fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 20 (1): 181. https://doi.org/10.1186/s12967-022-03386-4.

———. 2024. “Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Cachexia, Sarcopenia and Muscle 15 (3): 838–48. https://doi.org/10.1002/jcsm.13442.

Wyller, Vegard Bruun, Kristin Godang, Lars Mørkrid, Jerome Philip Saul, Erik Thaulow, and Lars Walløe. 2007. “Abnormal Thermoregulatory Responses in Adolescents with Chronic Fatigue Syndrome: Relation to Clinical Symptoms.” Pediatrics 120 (1): e129–37. https://doi.org/10.1542/peds.2006-2759.

1 The Paradoxical Immune State Hypothesis

2 The TRPM3-GPCR Signaling Convergence Hypothesis

3 The Systemic Channelopathy Hypothesis

4 The “Wired but Tired” Ion Channel Explanation

5 The Calcium-Mitochondria Cascade Hypothesis

6 The Post-Infectious TRPM3 Acquisition Hypothesis

7 The Temperature Dysregulation Connection

8 TRPM3-Targeted Therapeutic Speculation

9 Two Calcium Subtypes: A Unifying Framework

10 Subtyping Implications

11 TRPM3 and TRPM7 Dual Channelopathy

12 PIP2 Depletion as the Convergence Mechanism

13 PLC-Delta Positive Feedback and Self-Sustaining PIP2 Depletion

14 Store-Operated Calcium Entry and Futile Cycling

15 ER-to-Mitochondria Calcium Transfer: IP3R/VDAC/MCU Axis

16 The Expanded TRP Channel Sensitization Hypothesis

17 TRP-Targeted Therapeutic Approaches: Ambroxol as TRPV1 Antagonist

18 TRP Channel Pentamerization: A Structural Escalation Mechanism

19 Arteriolar TRPV1 and PEM-Associated Vasoconstriction

20 TRP Family as a Coordinated Sensory System

21 Cross-Disease Bridges: TRP Channel Parallels

22 TRP-Targeted Therapeutic Extensions

23 Diagnostic Implications: Vascular TRP Assessment

24 TRPV1-Thermal-Autonomic Axis: Thermal Challenge as Controlled Autonomic Stress Test

25 The Piezo1-RBC Microcirculation Hypothesis

26 Piezo2, Proprioception, and Mechanical Allodynia

27 Multi-Parameter Immune Calcium Biomarker Panel

28 Sodium MRI + TRPM3 Assay: Subtype Identification Protocol

29 Post-Infectious Channelopathy: Brugada Syndrome Parallel

30 GsMTx-4 as a Research Tool for Piezo1 Testing

31 Updated Testable Predictions from TRPM3 Research

References

12 PIP₂ Depletion as the Convergence Mechanism

13 PLC-Delta Positive Feedback and Self-Sustaining PIP₂ Depletion